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PREP'AOE 
Cholesterol is one of the most widel¥ distributed 
ore!;anic compounds ill animal tissues. Altho~ it has been known 
for over two centuries and. hat~ been the obj ect of numerous 
chemical and biochemical investigations, maD¥ functions of 
cholesterol are still not completely understood. 
Today, cholesterol is bains implicated as a patho&en 
!.!:!!:. g.eneris. It has been known to be a constituent of t;all-
stones ever since the compound was first mentioned in the 18th 
century. It is speculated that it m~ play an important role 
in the etiology of cancer and atherosclerosis. 
In the populQ1' mind, cholesterol and atherosclerosis 
are resarded as almost sjDonymous. Although a connection between 
the two seems definite, the extent of the relationshi~ is still 
controversial. The implication that cholesterol is an import~t 
factor in the etiology of atherosclerosis has come from 
consistent observations that this syndrome is prominent in 
states accompanied by hypercholesterolemia. The most important 
of these states, by virtue of its prevalence, is diabets 
mellitus. Literature data on diabetes mellitus shows very 
conclusively that there is an increase in the incidence ot 
atherosclerosis among diabetics. 
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With the discovery of insulin and the oral hy~ogly-
cemic compounds, some of the effects of diabetes mellitus have 
been controlled. There is, however, still a que~tion as to 
whether the accompanyiD.b hypercholesterolemia is reduced by 
these 8sents. Since many investib8tors believe that if the bio-
synthesis of cholesterol is controlled, the blood cholesterol 
will also be controlled, a study was Ulldertaken to elucidate 
the effect of the h¥~oSl3cemic compounds: tolbutamide, ph en-
ethylbiguanide, cp!orpropamide, and ,metahexam1de. on cholesterol 
biosynthesis !a ~v_l_tr_o_. 
Recently it has been reyorted that procaine therapy 
was effective, among other things, in the treatment of high 
blood pressure aJld heart disease. Therefore, the efiect of 
procaine (p-aainobenzoyldiethylaminoethanol) on the biosynthesis 
of cholesterol in vitro will also be studied. 
-
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HIHTORI 
The compound known as cholesterol was initia.l..i.J' 
described in the first half of the 18th centur3- As early 8.8 
1753, Vallisnieri (237) reco~n1zed that ball-stones were 
soluble ill alcohol. De Fourcroy (71) in I'lB:j mentioned that 
PolJ.etier de la Salle isolated a constituent of gall-stones 
some twenty .:rears earlier an~ Showed that the substance iso-
lated could be obtained as wb! te cr'ystalline leal'lets i.·rom 
alcohol. De It'ourcroy (71) isolated a 1ar~er quantity of the 
alcohol soluble substance, whiCh he believed was the same as 
spermaceti and that it was related to "adipocire", a matter 
obtained fro", acid tre;J.tment 0:1' grave wax, a substance formed 
in moist places in cementaries duriDb decomposition of tue 
bodies. 
Gren and ConL'a.di (60)(102) confirmed this fact and 
recognized tllat the same constituent 01' sall-stones coul;1 be 
obtained bJ ether extraction as well. Chevreul (>j) in 1815 
showed that the alcohol soluble substa.nce obtained from bal1-
stones was dit'lerent from spermaceti and ftadi,eJocire tl by virtue 
of its beinb unsaponifiatle and that its meltin~ point was 
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different. He ~ave this substance tile oribinal desi~atiun 01' 
cnolestrine from the Greek: chole, bile; and !!~, solid (54). 
With the knowledt!)e that cholestrine is found in the 
unsaponifiable portion of fats, it was subse~uQntly identified 
as a constituent of human and animal bile (97), tumors (1~9), 
hwnan blood (3d), brain (06), and e6t5 yolk (1,,0). Thereat-teL'" 
cho~estrine was reco~nized as a normal constituent of all 
an~ma.l cells and several secretions, as well as a comjJonent 
of patnolo~ical deposits (168)(~~~). The fact that cholestrine 
had an esterifiable hydroxyl brouP was shown by Berthelot (24). 
At that time the name of the compound was changed to the more 
descriptive "cholesterol." Cholesterol esters of oleate and 
palmitate were isolated. by Hurthle (111) in 1896. In 1909, 
Rosenheim and Tebb (200) four~d palmitate and stearate esters 
of cholest.erol in normal adrenals. 1lhe fact that cholesterol 
is deposited. in atheromatous aorta as tne este~' was shown by 
~Jindaus (257). 
In 1846, Gobley (9b) showed that cholesterol from 
e~bt ~al~ and bile was identical. This was later confirmed by 
;l1eno:t.zi (l!)~:.n. The existence ot: a d.ouble bond was indicated 
when Wislecenus and Moldenhauer (260) succeeded in ~reparlne 
a dibromide derivative of chole8te~'ol. The :first exact empirical 
formula of cholesterol was achieved by Helnitzer (191) in 
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1888 from the analysis of' cholestel.'yl acetate dibl.'oJilide. The 
conversion 01' cholesterol to cholestanone, car.ciad. out by 
Diels and Abd.erhalden (72), proved that the alcohol group is 
secondary. 
The elucidatioll of' structure was due to the work of 
\dndaus (.2.58). Aided by the studies of Wieland (2~c:) on the 
related bile acids, Windaus (258) in 191j arrived at a tenta-
tive formula, which in 1932 was changed to the one now accepted. 
Evidence leading to t.he correct formulation was prvvided by 
several workers. The new formula was based on X-raJ' studies 
by Bernal (26) and the finding of chryselle by selenium de4Ydro-
~ena tion of cholest erol. i'rom Diel' s and Bernal' s f'inJ.ings, 
Hosenheim and. King (198) sUOf;.>ested a perhydrochrysene 
structure, and later on the finding of' "Ueland and Dane (2,52) 
in rebard. to the size of rine B, the cyclopentano.tJerhydro-
phenanthrene st.z:'ucture was adopted (198) (1)'1) (2.52) to 1'1 t the 
data. 
CIlliMICAL h.l!.ACl\r01~S 
Since most of the reactions of cholesterol occur at 
the hydroXSl ~rou~t at the double bon~, or at carbon 7, the 
chemistry of cholesterol is not very involved. An under-
standi1l6 of a lare;e number of reac tions 01' cholesterol involves 
a cOl,sideration 01' the conformation of trle molecule. The 
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conformation of chol~titerol was suggested by Barton (l~)(lo) 
based on the conformations of cyclohexanes. The chair form of 
cyclohexwle i8 thermodynamically more stabl~ (21) and in this 
conformation two types of: carbon-hydrogen bonds are evident. 
The bonds joined at ri~lt angles to the ~eneral plane of tile 
rin~ were orie,inally cal.ied "polar" but are no'W. referred to 
as "axial" anl.1. those that are in the general plane ot tlle ring 
are called "equatoL'ial u (17). 
The equatorial position is more reactive in reactions 
depending upon the accessibility ot a substituent, su.ch as in 
esterification and hydrolysis. Heactions dependinb upon an 
attack at the hydrogen atom proceed more rapidly when tne 
hydrogen atom is equatorial. Ionic elimination reactjons 
proceed more rapidly with the elimination of two axial 
substituents from adjacent carbon atoms. 
The hydroxyl grou~ of cholesterol beillB e~uatorial 
is freely reactive. It forms esters, and ethers; it may be 
oxidized; it may be replaced by haloben; and it can be removed, 
under certain conditions, as water. The dehydration of chole-
sterol was i.rutially reported. by ;~uthner and Suida (155). 
Action of strong acids may cause polymerization of cholesterol 
to bis-cholestadienes (40)(189). 
Oxidation oi.' Cholesterol to cholestanone may be 
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achieved by the 0pj;enauer metiJ.od (1,(4), or by heatillti alone or 
in the presence of a suitable metal catalyst (ljb). :t'he esteri-
fication and etherification of Cholesterol may be achieved oJ 
conventional methvds. ~hen cholesterol is treated with thioD3l 
chloride or phosphorus pentacnlorlde, choleste.L'yl chloride is 
formed (73)(152)(155). 
The double bond in cholesterol undereoes the usual 
aJ..iition reactions. The .bydrogenatioll of cholesterol over 
platinum yields onlJ cnolestunol (2;;5). It has been known :t'or 
many years that cholesterol forms a dibromide (lj2) anti a 
di.chloride (1;';», but that t\\O isvmt.:ric dlhn11des JIJUV be 
obtained. 1s a fairly recent obsel:vation (lts)(1:J)(20)('~»)(1)o). 
:t'he routes of formation 01' the cholesterol dihalidos a.t.J,tlear 
to involve the anti-f~Kownikorf additiun of !lalide to an 
interr.'1ediate halonlum ion sUt!,gested. by }'leser (85) and 
co.n.firmed. by Barton !l!!. (20). The brumination 01' cllolesterol 
was formulated as involv1ne a rear a~tack and ilsoion ot an 
alpba-bromonium ion. ~he double bond of cholesterol 1s also 
reactive toward oxidizing agents ~iv1n~ diols or oxides. 
Be~lD6anate oxidation ~ives the 3-beta-5-alpha-b-
3.l i)hd-triol (cis h,)'dl.'ox,ylation) (2)6) as d.oes osmiwn tetroxid.e, 
i\hose complex with cholesterol haB been iSOlated by (.;.1'18-
t,.ee (68)(2;u). ~ihtfn hydL'ogen peroxide, performlc. or jleriodic 
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acid is uHed, trans hydrox,ylation is observed (8b)(j'j)(I.;jO). 
uxidation 01' cholesterol dibromide by acid. permanganate yields 
prot:;,esterone and cll.olestanone (21')). 
Bromination of cholesterol at carbon ? (beta) may 
be obtained boY using N-bromosuccinimide <.,0) (2u-;J) or by 
irradiation of chloroform solution of cholesterol and. 
bromine (208)(20'::1). Under proper conditions N-bromosuccillimide 
will also yield eholestane-3-beta-5-alpha-diol-6-one. The 
7-bromo compound 1s of great interes~ in ~hat it can be de-
hydrohalogenated with dimethylaniline (47) or collidine (27) 
to yield ?-dehydrocholesterol which ~ives vitamin Dj after 
irradiation. 
~,hen isotopically labeled acetic acid is administered 
to an animal, or 1s added to the incuLatioIl medium of tissue 
~reparations, isoto~ically labeled cholesterol can subsequently 
be extracted from the organs of the animal or fL'om tne tissue 
pretlarations. This, essentially, was the discovery re,I/OL ted b.r 
Bloch and Rittenbere; (3;') in 1942 and Bloch, Borek, and Ritten-
ber6 (34) in 1)40. After a number of isotopically labeled 
substances were similarly tested, it turned out that labeled 
cholesterol arose on13 :from those that weI'e known to 'be meta-
7 
bolized via acetate. 
600n after the originul discover., of Bloch and 
hittenbert; (35) was made, Little and Bloch (137) showed t.l:lat 
both t.l. .. e side chain and the nucleus of choleste.L~ol aC'iuired 
the label from isotoklic acetic acid aud that botn carbon atoms 
of the acid we.l.'e used for synthesis. They fed doub1.1 labeled 
acetate (C14H3c1302:Na) to rats and lou.nd that the ratio of 
Cl4 to C13 in the synthesized. cholesterol was about ;;:4. 
Assuming toot all ttl.e carbon a toms of choles I..e,,'ol were deri veel 
from acetat..e, the result sUr;..tJested tnat of tJ .. e 27 cW:'bons of 
cholesterol, 15 were derived from the meth.Yl and. 12 :.r.i.'om the 
cal:box.Yl atOJll of tile acid. The hypothesis was later confirmed 
by chemical debradation of cholesterol synthesi~ed by using 
radioa.cetate labeled. first in the methyl 'pOSition and then in 
the carbox'yl position (53)(54)(3~)(bj)(70)(204)(206). The two 
t:;;roups of carbon atoms 01' cholesterol shown to be de~"i ved from 
tile carboxyl and from the methyl carbon of acetate are repre-
sented in (1) by "C" and Itltll" resJ)6'ct1vely. 
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Although the ini'orrllation about the individual enzymes 
conc(;rned is meati>er, it is now possible to outline most 01' the 
reactions 01 sterol biosynthesis form acetate. ~ith the inter-
mediates betlJH .. en lanosterol and cholesterol beine:, ommitted, the 
mown biosyuthetic se'tuenca in the :formation of cholestex'ol 
from acetate is swnmerized. in Scheme I. ~allce bot.h aceto-
acetyl-eoA and mevalonic acid are intermediates in cholesterol 
sjnthesis, substances which directly or indirectly contribute 
to the formation of the twv intermediates are also included 
in the scheme. 
There are three places in the cholesterol molec~le 
where a repeating pattern of five carbon atoms, containin~ 
acetate meth31 and carbox,yl atoms in an isopentane structure 
can beseen. This fact was first recognized by Bloch (266) 
after debradation of the side chain of cholesterol biosynthe-
sized from cl4-labeled acetate, and prompted him to revive the 
old hy-pothesis that sy,ualene (II), a dihy'drotriter,tJene, is an 
intermediate in cholesterol biosynthesis (32). 
(; C c 
I I I 
c c c c c c c c c c c C / ~/ \/ ~/ \/ \/ \/ \1 \/ ~/ \/ ,\/ 
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, I , 
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Squalene had been sUb~ested as beiD6 involved in the 
biosynthesis of cholesterol as early as 1926 by Heilbroll, Karum 
and Owens (105). This was supported by Channon (51) who found 
an increased cholesterol content in the liver ot rabbits which 
were ted squalene. The first experimental j,Jruot that; sy'ualene 
was a j,Jart 01' cholesterol biogenesis was obtained byLan~don 
and Bloch (128) who showed that s~ualene was synthesized by 
rat liver from acetate. The conversion of squalene into sterol 
has since been confirmed by Aaudbal',Tchen and Bloch (154) 
who obtained the conversion of s~ualene into lanosterol. 
The torei:)oine) discussion slUumarizes the known bio-
synthetic pathway of cholesterol to 195b. The rec06Ilition 
of the pattern of acetate carbons in the isoprenoid units 
stimulated extensive research on the ori"in of C and. C 
t) 5 b 
branched chain acids as the source of isoprenoid units used 
in the biosyntnesis of squalene and sterol. A number of known 
branched chain aCids, such as 3-hydroxy-'-meth3l glutaric 
acid (HMG) , 3-methylgluconate, iso-valerate, and 3-methyl-
crotonate, were implicated in the b10synthetic pathway, but 
nOlle 01 these provided positive proof" 01' the idel.l.tity with 
an illtermediate betw~en acetate and squalene. The synthesis 
of 3-h3droxy-3-met4J-l ~lutaric acid (l~G) from acetate was 
demonstrated as early as 1952 by Bloch (32) and ulthoU6h it was 
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proposed as early as 1954 by Rudney (202) as a possible inter-
mediute between acetate and squalene, it was only after the 
discovery of mevalonic acid that the asymetric mOllocoenzyme A 
ester of 3-hydroxy-3-metbyl gll.ltarate, not the free acid, was 
recognized as its precursor. 
The discovery of mevalonic acid was the result of 
research related to bacterial metabolism and not to cholesterol. 
]olkers et ale (202)(263) found that "distillers 801ubles'' 
--
contained a factor which could repla~e acetate in sup~ortin~ 
the growth of an acetate-requirin~ mutant of Lactobacilus 
Acidophilus. When isolated, ~he factor proved to be the 
lactone (Ill) of the opticallT active ~,5-dihydroxy-3-methJl­
pentanoic acid (IV) and was named mevalonic acid. The resem-
blance of the acid (IV) to 3-bydroxy-3-methyl glutaric acid (V) 
~ave rise to the speculation that it might be involved in the 
biogenesis of cholesterol. Finally, Tavormina, Gibbs and 
HO, ",OR, 
/0, 
H21 yH2 
H20, /0 • 0 
o 
(Ill) (IV) (v) 
Huff (;227) showed that rat liver hOJa06ena.tes which were 
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relatively inefl icient convel'ters of acetate to choles \"el'ol 
were able to convert mevalono-la.ctone-2-C14 almost quanti-
tatively to cholesterol. The rest of the chapter will deal 
witn the discussion of the individual steps that leaJ £rom 
acetate to cholesterol. 
J~ctivati()n of acetate to acetyl-CoA and condehsation 
of" this to acetoacetyl-GoA are well established reactions 
~hich are not peculiar to cholesterol biosynthesis. liihe next 
stage, a condensation of acetoacetyl-poll. with acetyl-CoA, has 
been studied by Hudney (20;) and Lynell (14,). The enzyme 
responsible for the reaction, HMG-CoA-condensin~ enzyme, has 
been partially purified from yeast (84). The process liberates 
one molecule of coenzyme A, which comes :from tile acet.!l and 
not the acetoacetyl group. (llhe product, -,-hydroxy-3-methyl 
elutaryl GoA (HMG-COA) is formed as shown in Scheme 11. The 
reaction is not easily reverSible, but HMG-CoA can be irre-
versibly cleaved by anothe,c enzyme t HMG-CoA cleavage enzyiIle t 
to acetoacetate and acetyl-CoA (203). This, in eflect, produces 
a hydrolysis of: acetoacetyl-CoA and is thought to produce :free 
acetoacetate in the liver (11). 
The synthesis of ID4G-COA does not come e~clusively 
from acetate. jl.llothe~" potcnti:.d source of H,,1G-CoA is the 
biotin-dependent enzymic carbox¥lation of 3-methyl-3-hydrvxy-
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butJr31-CoA and 3-methylcrotonyl-GoA (02). Bince both of these 
substances are metabolites of leucine, the amino acid is a. 
distant precursor of cholesterol. The incubation of leucine 
or leucine metabolites and carbon dioxide with rat l.iver 
ho.tlloe;enates does yield cholesterol (31). 
The synthesis of lliAG-CoA to mavalonate by a soluble 
enzyme system from yeaut has been reported bJ Durr, Rudney and 
J!'ert;U80n (77)(83)(204) and by !;ynen (141)(146). It is aptJarently 
catalyzed by a single enzyme, ~G-Co~ reductase. The enzyme 
contains sulfhydryl groups essential for the catalytic activity 
as indicated by the severe inhibitory ef1ect of p-hydroxy-
mercuribenzoate, and the requirement of ad~ed thiols to 
maintain the activity of the purified enzyme. l."or every mole 
of HJ.llG-COA reduced t one mole of mevalonClte is formed t two 
moles of TPh~ are oxidized, and one mole of coenzyme A is 
released. The reduction of HMG-CoA was shown to oCGur on the 
thiol-esterified carboxyl group. Mevaldic acid (VI), ~hicll was 
HO, /CH3 
c 
/". H2Y 7H2 (VI) 
CHO C02H 
previou.sly ~resumed to be a part 01' cholesterol biosyut.i.lesis 
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was ~roven by Durr and Hudney (76) not to be involved. 
The :t'act that the :t'ret:: aldehyde, mevaldic acid, is 
not an intermediate in tne reaction does not pl:t!clude the 
pos~ibility tbat mevaldic acid is an intermediate in the bio-
synthesis of cholesterol. The possibility that enzyme-bound 
mevaldic acid or its thiohemiacetal are intermediates still 
remains. Although free mevaldic acid is not an intermediate in 
the reaction, tAe conversion of mevaldic acid to mevalonate 
can still occur through a side reaction. l!'or exampl.e, Durr 
and J.(udney (76) have observed a TJ?NH-dependent reduction o:t' 
mevalonic acid in certain yeast preparations, and Johns~one (118 
has reported the presence of a DPNH-de~endent mevalonic de-
hydro~enase in yeast. The products of these reactions have not 
been identified. 
Schlesinger (211) has reported a DPNli-dependent 
mevaldate reductase yielding mevalonic acid. This coUld explain 
the reports of Wright !1 ~ (265) on the biosynthesis of 
mevalonic acid from mevaldic aCid, and. also the findin~ of 
SChunk at ale (21;) ti~t unlabeled mevaldic acid depressed the 
incorporation of labeled acetate into sterol. The overall 
reaction, therefore, probably proceeds in a two step manner 
with an enzyme bound mevaldate or its thiohemiacetal being 
an intermediate in the reduction. It is ap~arently catalyzed 
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by a sir.ible enz.rme. Severa.l t~o-step reactions are assumed to 
be catalyzflid by a sin~le enzyme, and. such reactions apparently 
yroCeed through enzyme bound intermediates (l'l2)(~lQ)(~2o). 
The striking feature 01' this reduction is that it 
is iI'reversible. Attem,Pts to reverse this reduction have not 
been successful (18u)(195). HMG-CoA red.uctase, whatever the 
source, is stereospecific for the natural opticul enanthiomorph 
(+) of H~G (83). Interestingly, all the early sta~es of chole-
sterol biosynthesis are electro~hilic reactions at a carbonyl 
6rouP, akin to Aldol condensations, with coenzyme A playing 
its normal biochemical role 01' enhancint;; the electron deficit 
at the carbonyl carbon. As far as it is known, once mevalonic 
acid is formed t coenzyme A is no lont-er required for furti.ier 
reactions. 
The second phase of the biosyntllesis of cholesterol 
involves several enzymic reactions which convert mevalonic acid 
to squalene. Most of these reactions are s.t/eculCtive and only 
a :few of the enzymes involved have been isolated and purified. 
As a preliminary step to the investigation of the coenzymes 
involved in tile conversion oJ:. mevalonate to squalene, FopJak 
and Cornforth (18)) examined the various fractions of homo-
e:;enates obtained by centrifut<;at10n. liost 01' the enzymes necee-
seary for cholesterol and. squalene synthesis weJ.'e f'ound to be 
4. 
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in the mic.t:os01l1e8 (8104 fraction) and in the supernatant 
obtained from the 8 104, fraction. After the precipitation of the 
proteins in the Bupernatant, f'ollowed by reconsti tu l.i01:' of the 
proteins in 0.02 M potassium hydrogen carbonate and by dialysis, 
most 01: the ellzymes neccessary for the hio synthesis of' s~ualene 
and cholesterol are obtained. Together with the microsomes, 
the dialyzed 8104 supernatant was able to incorvorate mevalonic 
acid into squalene maxil1:lally. However, D.PN, Tl)N, and ATP had 
to be added to the incubations, othe~wise no incorporation of 
mevalonic acid into squalene could be obtained. The microsomes 
are neccessary for the synthesis because they c ontain an ~m­
compound, hiehl.1 sensitive to oxidation, and which is essential 
in the reactions preceding the formation of squalene. 
The fact that the liver enzyme sys"ems required ATE 
:tor the conversion of' mevalonic acid into squalelle sUoe,ested 
that phosphorylating reactions were involved in the biosynthesis. 
T1Jhen (228) was the first to report the formation of 5-vhos'pho-
mevalonate (VII) from mevalonic acid and AT.P using a yeast 
enzyme prevarat1on. The same reaction was also identified as 
taking place in I'at liver pL'eyarations (195) (2i tO) (2i H). 
Tcllen (2.;:>j) partially purified the enzyme by treatment of a 
\ hioh speed supernatant o:f yeast 8utc:alyzate with .protamine, 
followed by fractionations with ammonium sulfate aIhl calcium 
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phosphate ~el. The product that was formed ~fter the phospho-
I'+- ,- '1)~ 
rylation contained (.; and P' in a ratio of 1:1 when mevalo-
nate-2-C14 and A'rp32 was used. Direct chemical analYBis of the 
substance isolated from the liver incubation also showed that 
it contained one atom of phosphorus per molecule of the pro-
duct (212)(240). Since it gave no hydroxamate and was stable 
to alkaline and acid hydrolysis (212)(228) and since the free 
acid failed to lactonize (141)(212), the must probable structure 
appeared to be that of 5-~hosphomeva~onate. The identity of the 
phosphorylated product was finally established as 5-phospho-
mevalonate by chemical phosphoI71ation ut· wcvalonic acid (87). 
t,levalonic acid, therefore, by the action of mevalonic 
kinase, is .vhosphorylated to yield 5-phosphomcvalonic acid. 
The enzyme involved in the reaction seems to be an 8H-enzyme 
since it is inhibited by p-chloromercuribenzoate. dlevalonic 
kinase, whether from yeast or Ii vcr t 1s stereospec.ii'ic for the 
natural enantiomorph (+) of mevalonate just as H.MG-GoA. reductase 
was stereospecific for (~) HMG-GoA. The liver mevalonic kinase 
cannot phosphorylate mevalonic acid lactone or the 3-anhydro 
analot:jues of mevalonic acid (132)(153). When 5-vJ:lOS.t>ho-(2-C14 )-
mevalonate is incubated without AT?, there is no iJroduction of' 
sterol. This s~bested a further phosphorylation takes place. 
Althou~h a further characteriza.tion of' the substance is needed 
tne next intermediate seems to be 5-diphos~homevalonic 
acid (!:I5)(21~). The enzyme catalyzillt5 this reaction has been 
partially purified from pig liver by l~pjak (106) au~ catalyzes 
the reversible fOrtllation of 5-dij,)hos!-,llomevalonate !L'Olll 1Jhos,!,)ho-
, 
mevalonate and ATP. The positivn o:r eq,uilibrium lies on the 
siue of t.ne forward reaction and. 60es at o,.>timwn rate in the 
presence of Mg++ ions. As the phosph omevalonic kinase reaction 
is reversible, it is evident that the second ~!lOs.t:>llate bond in 
5-diphosphomevalonate is an enerbY rich bond, probably 01' the 
same order of magnitude as that o:f ATP. 
5-Diphosphomevalonic a.cid, by the catalytic action of 
di~h081Jhomevalonic anh3drocarboxylase, is then tr~sformed into 
isopentenyl pyrophosjlhate (3-meth.Yl'but-}-en-l-yl 'p'yrovhos~hate, 
V III) wi til the loss of one molecule ot' (;Oc~.. The decarboX.flation 
c. 
seems to proceed via a labile phosphate ester, ~-di~hos"pho-3-
since -,~2 contain~d in tn' e Am,3~ used ,tJhosphomevalon:J.te (IX) t .P' ... .r-
in tne reaction did not apjlear in the isopentenyl pyro»nos-
phate (55)(144). This compound, isopenteny1 pyrophosphate, 
a uecax'boxylation product of 5-diphosi-/hOmevalonic acid, must 
'be considered as the substance Wlder60in~ conu.ensd. tion to 
squalell8. 
Al though the formation of iso1,..'entenyl .i.Jyrophospl.l.ate 
and 1 ts incoI'poration into the s\.lualene mol~cule has been proven 
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to take place (144), the maruler in which this takes ~lace is 
still a subject of wiele research. Since at tlHl two ends 01' the 
s~ualene molecule the ~roupin~ (CHj)2C • CH - appears, it 
follows that an isomerization of' the isopentcn;yl pyrophosphate 
to a dimethylal.iyl structure must occur at SOUle stac;e. \;ith 
the partial pUL'ification of' the enzyme isopentellJl PYl.'ophos,Phate 
isomerase (144), which converts isopentensl pyrophosphate to 
dimeth31allyl pyro,Phosphate, the hy,Pothesis otthe isomerization 
of isopentenyl pyrophosphate was exverimentally proven. The 
reaction could be envisioned as beillb initiated by a proton 
followed by an elimination of a second proton from the molecule 
as shown in Scheme IV. 
The ssnthesis of squalene proceeds from a series of 
condensations invol.ing electrovhilic addition to doubly boUl~ 
metnylene ~roupa. Dimetb31allyl pyrophos~hate has the properties 
in com.Hon with other substances in which a hydroben, a hydroxyl, 
or an esterified hydroxyl (in this case esterified with a pyro-
phosphate) is in the alpha position to a double bond. hliUlina-
tion :from such substances may oct..!UI,' readily, 1'01' tIle resultint;> 
electron deficient species is 
between two equivalent forms: 
par~1a~ly stabilized 
" I O=O-O-OR 
( ...... C= C="' ....... )+ + OR-
./ I '" 
,,/ I I ---~, 'C=O-C4' /' ! " 
~ ."., 
-fC-O=C 
..."... ......... 
by resonance 
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The allene type substances are strono electrophilic l.'ea.c:.ents 
and could 8.'ttack a terminal methylene group. This electrophilic 
mechanism could occur either via the interm~diate ion or as a 
billloleculal.' displa.cement. 
The most probable first condensation leadines to the 
s'yllthesis of s,-,ualene, therefore, is bet.Vween dimetLyla11.ll 
P5rophosphate and isopenten,l ~yro~hosphate (143), with the 
elimination of pyro~hosphate ion from the dimethylallyl pyro-
phosphate (Scheme IV) by a mechanism just described. 'l'he con-
densation product, of course, carx'ies an excess of ,positive 
charge, but stabilization may occur by elimination of" a proton, 
among other ,possible processes, givine; rise to t;;eranyl p:/ro-
phosphate (14}). In geranyl 'pyrophosphate we have a~ain an 
electrophilic reagent, which can condense with another molecule 
of isopentenyl pyrophosphate in the same manner as the conden-
sation of the la~ter with dimethylallyl pyrophos~hate. Again 
by stabilization through elimination of a. lJroton, the product, 
farnesyl pyrophosphate (14}) is obtained. 
It is not known whether the two condensations are 
catalyzed by two different enzymes, but the formation 01' 
geranyl and farnesyl pyrophos~hates is readily demonstrable in 
a liver enzyme system. ~en !1 ~ (144) BYIlthesized dimethyl-
allyl pyrophosphate and geranyl pyrophosphate and obtained the 
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ISO.PENTEl~IL PIHOfhOSPHA'l'E TO GblRAN:iL PIHOPHub.PHA'r~ 
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formation of geranyl ana farnesyl pyro~hos~hates with an enzyme 
system pre~ared trom yeast and ~rom soluble supernatants of 
liver homogenates. 
Ifarnes,yl 'pyrophosphate t a Cl ,5 iso,Prenoid su.bstance, 
resembles squalene in the fact that a tail to tail condensation 
of two molecu.les would give rise to squalene. Tne a~~earance of 
nerolidol (X)(l84) in incubations of liver enzyme sJstems tiave 
rise to tl ... e speculation that farnesyl !>yrophosj:l.o.ate undergoes 
isome.cization to nerolidol pyrophosphate witll the two substan-
ces then condensiD6 in a tail to tail condensation yieldi~ 
s,,!ualene as the pL'oduct. The enz.yme responsil)le I'or the iso-
merization haG not been isolated. The conclusion that the 
reaction is a genuine enzymatic formation of the nerolidyl 
deriva'tive rests on the appea.l'ance of free neru.Lidol after 
hydrolysis ot' a mixture o:f polyprenol derivatives with snake 
venom phosphatase and also from the reduction of a :freeze-dried 
alkaline specimen of these derivatives with lJiAlh4 in ether (184) 
It seems certain, therefore, that there exists an 
isomerase which if;oLlerizes the farnesyl pyrovhosphate to 
nerolidyl pyrophosphate. The isomerization probably proceeds 
as a result 01' inteL'Ilal phosphate rearrangement (Scheme V), 
althoutf)l se,Paratiun and reattachement of p'yro.tlhos~hate ion 
constitutes another pOGsibility. 
SCH~l~ V 
1. Formation of farnesy1 ~yrophosphate: 
25 
farnes,yl 
J,)yrophosjloote 
2. Isomerization of farnesyl pyrophosJ:,)hate to neroridyl lJYl.'O-
phosphate: 
R -
0'-
nel.'olidyl PYL'ophosphate 
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By a previously discussed electrophilic process, 
farnesyl anJ nero1idyl pyro~hosphates could condense in a tail 
to tail condensation. The mechanism of this reaction has been 
theorized by Pol>Jak and Corn:forth (184) and is t<;;iv8n ill 
clcheme VI. It involves the elimination of ~'yroJ!hos~h"",te with 
subsequent electrophilic attack on nero1iJy1 pyro~hosvhate. 
The product, a hypothetical electron de£icient intermedi~te 
which still contains the pyrophos~hate of 11e.1'olio.01, could then 
become s1;ubilized by elimination of a proton, the pyrojJhos~lu te 
ion, and another proton to yield dehydros-iu,alelle. Althou~h 
debydrosqualene has no~ been directly implicated in the bio-
syn.thesis of cholesterol, it seems likely that it is an inter-
mediate since DPIHl is needed in the conversion of mevalonic 
acid to squalene (195). 
Recently sUPJ!ortlng evidence by Hi11iu6 and 1310ch 
(1':15) sUboests that the .b..Ypothetical condensa.tion of farnesyl 
and nerolidJl pyropnos~hates as postulated by PopJak and Corn-
forth (184) is 'pJ:'obably true. Their results indicat;e that out 
01' tile 12 jlossible deuterium atoms from (5-D~)-w.eva1ona te, only 
10 wel.'e cunt.ained in the molecule and the 2 t1..lat dissappeared 
were lost from the two central atoms of squalene. 
The relationship betwe~n squalene and lanosterol has 
been 'previously discussed. 'rhe cyclization of sy,ualeno to 
SCl~l~ VI 
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lanosterol is catalyzed by the enzyme squalene oxiJ.ocyclase I. 
'I'lle ini'Giating species actin6 on squalene is aSSUlaeu to be a 
cationic oX.I't;;,en atom, e.b. OU+. The assumption comes from the 
fact that WIl.en mevalonic acid is incubated with rat liver 
homogenates under an atmosphere ot nitrogen only s~ualene is 
synthesized. \\hen oxygen is substituted :for nitrot)en, chole-
sterol is almost the only product that can be isolated with. 
very little squalene (185). 
By attackin~ one of the terminal double bonds it 
creates a new cationic species which attacks the next double 
Dond, thereby producing a six-membered rino. The electro~hilic 
attack continues in the same manner until the ~artial1'y cyclized 
cation-olei'in complex Xl t Hcheaa VII, is 1ormed. The complex 
undergoes :further rearrangement to give complex XII. The 
formation of lanosterol is completed by m.it;;ration of two 
hydrogen atoms and by the expulsion of a proton fl.'om 09 to form 
the double bond at °8- 9- The evidence for these rearranbements 
has been provided bJ' isotopic labeliIl6 obtained '0.1 A~iawlt).,a.l, 
Tchen and Bloch (154) and by Corn~orth !l ~ (bj)(b4). 
The cOIlversion 01' lanosterol to cholt:sterol proceeds 
by a series 01' steps, not all 01 whiCh have been wOl.'.k:ed out as 
yet. The 1'i.rst 01' these reactions is tile oxidative removal of 
three meth.Y 1 groups from lanosterol (j4). 'ilhe reaction seems 
HO 
SGH1~\A}; V II 
TIi..c,; BlUS n1'iihl!~org Ul ~HUl.ili.~)IJ: .ll.Lf.0.L 
~:LtUA~E 'ro l.tA1."u;','.rl!;ltUL 
HO 
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to proceed via the carbox3lic analo6ues which are then decarbo-
x.ylated to ,yield :> molecules of c.;02- 'I'he ordeL' 01' tI. .. e removal 
oi' the methyl groups from positions 4 and. 14 is still unknown. 
After tne removal ot: t,ile three Illeth.11 gl.'OUpS, the ..1ouble bond 
at 8,,, .1.s replaced by a double bond at 5,6, :1' ollowed 'b:t the 
removal of tna double bond in the side chain of lanosterol. 
~ince this portion of cholesterol biosynthesis is still very 
uncertain, the reactions leading from lanosterol to cholesterol 
will not be discussed. A general pathway o'btailled .from 'preli-
minary experiments is shown in Scheme VIrl. 
Cholesterol is, therefore, entirely synthesized from 
acetate. By what appears to be an irreversible reduction of 
HMG-CoA in active equilibrium with acetate, mevalonic acid is 
formed which 1s then conversted into 1sopentenyl pyrophosphate 
having both nucleophilic ar~ electrophilic activity_ Utilizing 
both of these activities the,y 6ive rise to intermediates 
(6eraD3l and tarensyl pyro~ho$phates) by a head to tail voly-
merization. Farnesyl pyrophosphate then undergoes isomerization 
to nerolidsl pyroptlosphate, which then are somehow joined tail 
to tail to produce s",ualene. Sli.ualene retains nucleophilic 
activity, cyclizing to lanosterol, which eventually, by a 
series of reactions, produces cholesterol. 
CHAl?Tl£R I I 
Diabetes mellitas is a chronic metabolic disorder 
characterized. by a disturbance of lipid and carbohydrate meta-
bolism and manifested by a decreased tolerance to carbohydrate. 
The cond.ition develops either when the production of insulin 
is inadequ.ate, or when the action 01' insulin on tnetissues is 
antagonized. 
Many facts led. to the belief that the vaD.creas 
produ.ced a hormone which was neccessar~ for the norJJlal meta-
bolism of carbohydrates. In 1889, von Meri~ and. Minkowski (160) 
showed that the removal of tile pancreas caused diabetes mellitus 
It seemed likelT t.l:w. t tl,e ductless Islets 01' Lant::.erhans, whic h 
lie imbedded in the body of the pancreas t were tL.e source of 
a secretion, whose absence caused the syndrome. De Meyer (101) 
in 1909 8U6sested the name insuline for the hypothetical 
internal secretion of the 'pancreas. 
It was not Wltil 1922 that BantiD.6 and Best (12)(1,) 
(14) succeeded in extracting a preparation from normal pancreas 
containing the antidiabetic hormone in a form which consistantly 
alleviated all manifestations of diabetes in totally depaD.crea-
33 
tized dogs. In 1926, crystals ot insulin were isolated from 
pancreatic extracts (1). 
Insulin is a polypeptide which is rapidly destroyed 
by enzymatic action in the gastro-intestinal tract. Although 
attempts have been made to protect the insulin from beino 
dieested atter oral administration, preparations givin~ ade-
quate absorption when administered orally have been unsuccessful 
Daily inJections are needed for patients witn diabetes mellitus 
in order to maintain good health. Since it has been found that 
the action of insulin 1s influenced by the size ot the crystals 
administered (253), different preparations have been made 
utilizing zinc auspensioDS, protamine suspensions, amorphous 
zinc insulin, and different combinations of the above (71). 
By using different ratios of these preparations, 
almost any desired duration and strength ot action can be 
attained. Nearly maximal progress has been made with this type 
of therapy. Benefit would obviously be derived if the ~ancreas 
could be stimulated t. increaae the secretion of insulin by 
orally ad.Dl1nistered. co.pounds, or if the orally administered 
compounds could imitate the action of insulin in the treatment 
of diabetes mellitus. 
HISTOHY 011\ ORAL HYPOGLYCEMIC CO.MPOUNDS 
FlYer aince the isolation of insulin, a search for oral 
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hYpoglycemic compounds has been in erfect. In 1920, Frank, 
Nott~ and Wagner (90) reported the hy~glycemic effect of a 
diguanide. 81llthali.n. Graballl and Linder (100) studied this 
compound and found that it caused severe liver damage and it was 
soon abandoned as a hypoglycemic compound. 
Plant extracts have been used. a long time as remedies 
for diabetes mellitus in maD¥ parts of the world. For example, 
Allen (12) investigated. blueber~ leaf extracts and Hugh-
Jones (110) studied the extracts of periwinkle, mistletoe, and 
nicker berr7. Many other plants possess marked hypoglycemic 
properties. The two alkaloids, galepine (1&8) :from tile seeds 
of GaleRa otficinalis, and 1apanine (58), trom the seeds of 
LaQinus a1bus,. have the property ot reducing blood sugar ot 
normal individuals and diabetics. Other materials with hypo-
glycemic properties have been extracted from a wide variety 
of plant tissues. 0011ip (59) extracted from clams aDd m&D7 
plant sources, a substance, glucokinin, which produced marked 
hypoglycemia whell injected into rabbits, While Little, Levine 
and Best (1'8) found an insulin-llke substance in the disinte-
gration products of killed bacteria. Most of these preparations 
were usually toxic to the liver, which is probably wh¥ they 
had a hypoglycemic .ffect. 
Kassall, ReTle and Fing (106) isolated a hypoglycemic 
compound from the unripe "ackee", the fruit of a plant, Blighia 
sapida. 1his com~ound, which seemed to be a ~oly~e.ptide was 
called Bypoglycin A. Anderson !l ~ (6) and Ellington, Hassall 
and Plimmer ('78) determined that the hypoglycemic acti vi ty was 
due to an amino acid. whose structure is giv8Jl in Table II. 
A second h¥poglycemic compound has also been isolated from 
Blig4ia saRida and the name hypoglycin B was given to it (104). 
It is a gollPeptide composed of bypoglycin A and glutamic acid. 
A new era of h3pog1ycemic oral compounds began in 
1942 when Janbon, Chaptal, Vadel and Schaap (110) discovered 
that 5-isopropyl-2-aulfanilamide-l,3,4-thiadiazole (also called 
IP1D) possessed hypoglycemic properties. Although this compound 
proved to be very highly toxic and fatal in some cases, it 
opened an era of research on synthetiC hypos1ycemic compounds. 
Since then, a wide variety of compounds have been examined for 
hypoglycemic actioIl. These compounds can be characterized into 
three classes; the thiadiazoles, the arylsulfony1ureas, and the 
bibuanides. 
Between 1942 and 1946, studies on the mode of action 
of IFTD and other tniadiazoles in dogs and ratbits were made 
by ~ubatieres (139). From his studies came a general mechanism 
for the action of the thiadiazoles. He found that IPTD does not 
produce hypoglycemia if the whole pancreas is removed, but mal 
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do 80 if a8 little as one-sixth of the ~1an4 remains. It is 
most effective wheIl injected direct17 into the pancreatic 
artery and acts independently of the nervous system. It also 
lowers the blood sU6ar in inverse proportion of tne sul~onamide 
level of the blood and raises the respiratorJ quotient after 
glucose administration. Chen, Anderson, and Maze (52) bave 
re~orted a hy~og17cemic action of 5-c7clo.pr~'pyl-2-8ultan11-
amido-l,3,4-thiadiazole in intact rabbits. However, since the 
tniadiazoles were very toxic and sometimes hyperglycemic in 
animals with severe alloxan diabetes (52), they were never 
put into U8e. 
Interest in the field was enhanced by the studies of 
Franke, AChe1is, Betram et al. (2)(29)(91) on a new bypo-
--
glycemic com~ound, I-butyl-3-sulfonylurea (also called by ita 
generic name carbutamide). It was found, however, to be toxic 
and was withdrawn in October, 1956 from clinical trials. Since 
then many hundreds of chemeally related compounds have been 
st"adied for their hypogqcemic activity (49)(153). 
The majority 01' these compounds wel."e :found. to be too 
toxic for human use, but three analogues of carbutamide t namely 
tolbutamide, chlor~ropam1de, and metahexamide have been 
subJected. to clil'lical atud.ies, and two of them, tolbutamide 
and chlorpropamide are being extensively used for the treatment 
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of mild, adult, diabetes mellitus. The third, aetahexamide, was 
recently withdrawn from the market because it did not offer aQy 
important new beneficial features. 
THE ARIL8ULFO.NX'LUREAS 
Carbutamide (N-butyl-B'-sulfaD¥lurea, BZ .55, U 6987. 
!nvenol or Nadisan) 1s a white crystalline substance wh1cb has 
weak acidic pro»erties associated with the 8ulfanyl ~rou». It 
forma salts with alkalis and the sodium salts are easily 
soluble in water. The estimation of tree carbutamide can be done 
readily by diazotization and couplin6 reactions (59). The liver 
partially detoxifies caebutamlde by acetylation and then the 
compound is slowely eliminated by the kidneys. As with the 
other sulfonamide. containing a p-amino group, carbutamide has 
some antibacterial action and impaires the t~roid functioll (7) 
(44). 
The replacement of the p-amino 6rouP or carbutamide 
by a .etI~l group gives rise to the b¥po~l¥cemic compound most 
widely used in diabetes therapy, tolbutamide (.N-but,yl-N'-p-
to luenesulfonylure a, Rastinon, Orinase, D 860 or U 2(43). The 
change of the substituted group on the benaene ring is respon-
s1ble ror maD3 1mportant b10106ioal differences. It is a white 
crystalline solid with a melting point of 128.50 - 129.5°0., 
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and is ~ractieal17 insoluble in water, although it forms 
soluble salts with alkalis. It can be readily dissolved in 
acetone, chloroform, and alcohol. Various methods for the 
determination of tolbutamide in blood and urine have been deve-
loped (15o)(220)(2~1). 
In man, tolbutamide is converted into freely soluble, 
non-toxic, carboxylic acid (N-but31-H'-p-carboxy-phenylsulfonyl-
urea) b7 oxidation of the p-metnyl substituent (140). N-butyl-
N'-~-~ro~methylphenylsulfonylur.a.has also been found in 
blood in verr small amounts (204). Finall,., Mohni.k:e and 
Wittenhagen (164) isolated from the urine of do.s a toxic 
metabolite of tolbutamide, p-toluene.ulfonamide and another 
compound which was later shown to be p-toluenesulfonylurea (105). 
Scheme IX summarizes the .etabolic breakdown of tolbut .... ide. 
The elimination ot tolbutamide i. done br the kidners, 
mainly as the carboxylic acid (88). Tolbutamide, as contrasted 
with carbutam1de, does not affect significantly the thyroid 
function as assessed by 11'1 studies (151). The abolishment of 
the goiter-producing properties of the arylsul.fonylureas comes 
trom the removal 01' the p-amino ~roup (l48). 
Chlorpropamide (N-propyl-N'-p-chlorobenzenesulfonyl-
urea, Diabenese, P 601) is a white crystall1ne compound melting 
at 121., - 128.,00• Chlorpropamide differs from tolbutamide in 
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SCHEJ..tE IX 
THE METABOLISM OF TOLBUTAMIDE 
9-t olylaulroD¥lurea 
1 
tolbutamide 
p-toluene sulfanamide 
N-butyl-N'-9-carboxy-
~henylsMlfonylur.a 
c=c 
/ "-HOB2C - C ~ ~ C-S02lffiCONHBu ~c-c 
N-butyl-N'-p-h3droxymethyl-
9h enylsulfonylurea 
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the fact that the p-Jaetiql group of' tolbut8Jl.1de is replaced 
by a chlorine atom and the butyl radical 1s replaced by propyl. 
A single dose of olle gram of chlorprQpamide produced 
a signif1cant hypoglycemic e:f'1'ect in normal subJects ~reater 
than is produced by an identioal dose of tolbutamide (249). The 
b1010g1cal "half-11fe" of chlorpropamide is about }:> hours, 
which is approximately ten ti.e. than that of tolbutamide (225). 
In man. this compound. in contrast with tolbutamide. i8 pro-
bably not metabolized before excretion. fto definite chromato-
graphic or ultraviolet absorption differences have been found 
between the pure drug and that in serum or urine (117)(224). 
Using the urine of dog8 treated with cblorpropaaide-s;5, 
however, three d1fferent chromato6raphic spots were detected. 
They were identified as tlle uncha.r:L&ed compound, p-chlorobenzene-
sulfonylurea. and p-chlorobenaene.ulfonaaide. The thre. COJD..PQundl 
accounted for ;0. 40. and 20 per cent res98ctively. In rabbits, 
80 to 90 per cent of chlorpropamide was found to be excreted 
uncb.an&ed (197). 
The increased ~poglycem1c activity of ohlorpropamide 
as compared with tolbutamide is probably due to the higher 
initial and more prolonged blood levels attained and not to 
any inherent increased potenoy (67)(124). Tb¥roid function a8 
assessed by plasma protein-bound iod~e levels and the thyroid 
4; 
uptake of radioactive iodine is not impaired by cl~lorpropa­
mide (217) • 
Metahexamide (N-cyclohexyl-N'- (3-amino-4-toluene-
sulfonyl)-urea, Euglycin) is a very effective hypoglycemic 
compound with a duration of action which is longer than that 
of chlorpropamide. It is about as half as effective as chlor-
propamide and abo~t five times as effective as tolbutamide in 
producing sustained blood levels (124) • Dogs and rabbits 
excrete 30 to 35 per cent of the administered metaheaamide dose 
unchanged in the urine and 40 to 50 per cent as 3-a.m1no-4-
benzenesulfonamide (197). Since it was found that metanexamide 
caused obstructive jaundice (89)(147), the compound has been 
withdrawn from clinical studies. 
It is generally agreed that in mammals the ar;rl-
sul.foqlureas produce hypot!)lycemia onll' when some functioning 
pancreatic beta-cells are present. Roussay and Penhos (109) 
showed that the presence of some pancreatic tissue is essential 
for the hypoglycemic effect ot the arylsulfon,ylureas in the 
same way that Loubatiere. (142) showed that this effect was true 
of the aulfanylamidothiadiazoles. The arylsulfoD¥lureas reduce 
the faatlng blood sugar level of intact and partially pancrea-
tectomized or mildly alloxan-diabetic animals, but they do not 
do so after total pancreatectomy in dogs, rabbits, rats, o. 
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man (l~;)(250), nor in animals made severly diabetic with 
alloxan • 
.li1X'l.'lUlllliPA.l. Ie .i!;Jtl< i!,;~'.r:) OJ! AHY·U;U.LI!OI'f Y.LUhl!..,\;;i 
The mechanism by wIucn tolbutamide and other h¥po-
blycemic a.L',ylsull'on'ylureas exert their h.fpoelycemic actioll is 
still dis~uted. Like tolbutamide, the arylsulfonylureas are at 
best poorly efi'eetive in the absence of functional .vanereatic 
cells. Althoubh the evidence indicates t!~t ~heir administration 
results in decreased paneL'eatic insulin (ltld) and increased 
insulin-liKe activity in the .vancreatic vein (1'1'1)(187), l1J.a.D:3 
metabolic effects which accompany arylsulfoLylurea induced 
hypoglycemia are so different from tilose whier.!. accompaD¥ 
insulin indUCed hypoglycemia that some investibators postulate 
the presence of major extrahepatic factors 01' arylsulfonylurea 
action. 
Tolbutamide and chlorpropamide added !a vitro, using 
rat liver slices, have been found to d.ecrease ciJinephl'ine-
induced glycogenolysis (238) and ketogenesis (37). I',b.el ... rat 
liver homogenates were used., tolbutamide was found to alter a 
number of en~atic activities, including at least one trans-
aminase (36), several D.l)N and TPN requiring systems (244), and 
the 'phosphorylase redctivating system (2!:». Tolbutamide and 
ehlorpro~amide administered !a ~ decreased ketobenesis (,8) 
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(42)(12,)(1')4). Tolbutamide administered!!!. !.!!.2.t with the 
efiect measured either!!:. !!!.2. or !avitro t has been found 
(a) to decrease glucose output (210), (b) to increase the 
synthesis o-r glycogen, fatty acids and protein, witilout tne 
corres.,Vondinb extrahe1.Jatic effects seell with insulin (193), 
(c) to decrease the conversion o-r fructose and t,alactose to 
glucose (9)(190), and (d) to alter the levels 01' nwnerous 
enzymatic activities, including increased activity of malic 
enzyme (244). 
Chlorpropamide may, under ceratin conditions, 
slishtly increase the ~lyc06en cOlltent of rat diaphragm, while 
, 
under similar conditions tolbutamide has no effect (.57). Chlor-
~ropam1de also moderately depresses glutamic~oxalacetic trans-
aminase activity in the livers of well fed animals (207). These 
scattered reports are compatible with the hypothesis that the 
arylsultonylureas affect enzyme reactions which de~end upon 
pyridine nucleotides as co-:f):ictors (243). 
THE GU~,IDrN~ DERIVA~IVES 
In l')C:!b, lirau.k, liothman and Watiner (':JO) syntnesi2.ed 
Synthaliu A (decamethenediguanide) after earlier re.,Vorts stated 
that the administration of buanidine lowers the blovd-suear 
concentration (240). A few diaLetic 'patients were t.J.eateu with 
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synthaLin A, but it was subsequently proven to be quite toxic 
even in small doses (28), producin~ histolo~ical chan6es in the 
liver and kidney and all clinical use of the comj:Jound was 
discontinued. 
In 1'15'1, the llyp061ycemic af'fect of' pheneth,ylbit,:)uanide 
(N'-beta-phenethylformamidinyliminourea hydrochloride, DBI, 
Phenformin, Dibot1n) was described by Schapiro, Parrino and 
.Freedman (214). TheJ investigated appro:x.1.mately two hundred 
mono- and dl- substituted a~l and aromatic derivat1ves of 
formamidinyliminoureas, and found that phenethylbi6uan1de was 
a hi~hly active oral hypogl'ycemic compound in both normal and 
alloxan-diabetic animals. 
The mode of action of phenethylbit)uanide is dif:ferent 
from that of tli.e arylsulfony1ureas as the compound produces 
hypoglycemia in pancreatectomized animals (170), in severe 
alloxan diabetes (234), and in patients with Juvenile or 
insulin-deiic1ent type of d1alJetes (181). Pheneth'ylb1buanide 
increases tlle b1u.cose uptake by the rat diaphra&ll !!l vitro t 
while the muscle e1ycoben content decreases (2)4). A. max'ked 
increase in lactic acid production and a decrease iu oxy~en 
consumption SUbbest that pheneth'ylbi~uanide atimu1ates anaerobic 
glycolysis by inhibitiIl6 oxidative enzyme systems. 
Wick, Larson and Serif (2)1), usinb aUipose tissue, 
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have shown that phenetbylbi6u&lide inhibits the oxidation o~ 
glu.co;::",~;, acetate and succinate and considerably reduces fat 
synthesis. In man, the blood pyruvate and lactate levels are 
raised (82) and there is no change in hepatiC vein glucose, 
urea, pyruvate or lactate, nor in the oxygen consumption of the 
liver (2,2). Lactate levels in the blood from the femoral 
artery also remain unchanged. Hypoglycemia ca"not be produced 
in normal humans by the administration of phenethylbiguan1de 
(82), although with intact animals a decrease in tHe blood 
su.gar concentration is easily produced. These results sugbest 
trUlt the effects of' .phenoth.Ylbl~uanide are lar~el'y mediated in 
the ¥oripheral tissues. 
The tissue anoxia sUb~ested bJ this evidence may be 
attributed to inhibition of cytochrome oxidase and succinic 
dehydrogenase {~2')(233)t but a decrease in oxidative phospho-
rylation would have tL8 same result. Later work sUbbests that 
biguanides inhibit the transfer of ener~ rich phoswhate bonds 
to adenosine diphosphate (126). 
P.benethylbiguanide has also been found to si~nifi­
cantly increase the levels of serum inorganic pnosphate (215) 
whereas the aryl.sulfonylw:'eas decrease the sel.'um. inorbanic 
~hosyhate (74)(97)(114)(225). ~111iams !l ~ (254) found that 
phenethylbit;;uanide inhibited phos"phor'y~ase phospl1otase, the 
enzyme catalyzing the conversion of phos~orylase a to phospho-
rylase b. ifhe.i also :found that th.e compound had no eflect on 
the activity of .vhosjihorylase a or ,phos,ithorylase b 01' on the 
enzyme de1Jhosphoj)I1os,Phorylase kinase which catalyzes the 
conversion of phosphorylase b to phos,Phorylase a • .tl.n inhitition 
of phoslJ.horylase phosJ:)hotase 1£ .... v... i ... tr;;;..o ... woul<.l favor un increase 
in tlJ.e a.mount of ,PLl.os,Phorylase a ,Present in the tissue. Since 
phosphorylase a is believed to be the fvrm of the euz7&e active 
in glycot!ienolysis t this could account for j,)art 01' the decrease 
in gl.fco~en produced by 'phenethylbi~uanide. 
PHOCAUtE 
Some thirty years ago it was noted t.tlat when procaine 
hydrochloride (p-aminobenzoyldieth.Ylaminoethanol hydrocnlol'ide) 
was useu as a pain killer, it had some the.t'apeutic value in 
artihz'i tis, nervous disorders and certain othe,r conJ.i tions. 
H.ecently t AsIan (10) has shown that procaine hydl'ochloride 
decreases atherosclerotic lesions. It was also observed that 
both the absolute and relative rise in the blobulin fraction 
was the same for .:)atienta as fur control::.>. On tile other .hand, 
the chanbes in the beta-blobulin fraction were more si~nlficant. 
In atherosclerosis, procaine chane:;;es the ratio 01' alj,lha to 
beta ~lobulins in favor of the former, thus actill~ like he~arln. 
when the cholesterol level of tile blood was measured as an 
index of lipid metabolism .. it waH found. tllat treatment witll 
procaine causes a rise of the mean values. ,;.slan (10) considered 
this as basically desirable and interprets this as due to the 
I!lobilization of cholesteI:ol rese.L"'ves t po!.)sibly as a result of 
tne hydrotropic ation of procaine. 
Smie;;el !! !..!!.. (21(3) t on the other hand, have found 
that a decrease in the blood cholesterol follOWS the aamini-
stration of' procaine. Out. of 2'1 'patie~ts treated with procaine 
hydrocllloL'ide. 23 had a reduced blood cholesterol level. TIle 
dr0.l:i in cholesterol ranged from 1.5 to 180 Jilt,;jlOO ml of blcaod. 
Serum calcium concentration increased in 17 out of the 2~ 
patients treated with procaine hydrochloride. 
Bucci and Saunders (46) have found that procaine was 
an ef'fective inhibitor of monoamine oxidase and is clinically 
effective in alleviating depression and reducillb psychotic 
symptoms associated with schizophrenia. ~)rom !E. vitro studies 
it. would ap'pear that p.I'ocaine is capable of' ini tiatine,. a clinical 
response by inhibition of three en:e:;yme systems: monoamine 
oxidase, polypheuol oxidase, and choline esterase. Philpot (179) 
has demonstrated that besides inhibiting monoamine oxidase and 
polyphenol oxidase. procaine also irdlibits cytochrome oxidase. 
Besides the inhibition of the above enzyme systems, 'procaine has 
, 
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il,l 
been found to have an antlhylJertenslve effect, reduclnt!. high 
blood ,Pressures to normal. 'i'he llon-h.Y,vertensive ,Pa.tients were 
found to have no significant changes in their blood pressure (4~ 
:i I, 
I, 
CHA1~EH III 
It is fairly v>rell establisheu. that tne cholt:ste.rol 
concentration in the blood seL'um is a 'px'i.lllary factor in the 
formation of atherosclerotic ~atches in blood vessels. Barly 
studies b.1 V,indaus (257) and Scnollheimer (212) ino.icatedtilat 
in atherOSC..LeI.'otic aortas the cholesterol COl.-tent was t5reater 
than that of normal ones. Both free and ester cholesterol were 
present and the ratio of free to ester cholesterol a9~roximated 
that fOWld in the blood • 
..Ha.rly invest.igators were able to induce atl.eL'osclerosis 
in rabbits by putting them on cholesterol rich diets (113)(206) 
(248). The use o~ cholesterol as an atnero6enic stimulus (8)(242) 
established it as the causative agent contained in the ~reviously 
mentioned diets. The name atherosclerosis was biven by 
i4archand (151) in 1905 to the lipid infiltration o~ tile intima 
which causes the amor'phous accumulation of tatt.y muterial. The 
theories regarding its genesis are many and varied, but whatever 
the tinal definition o~ the initiation of atnerosclerosis may be, 
there is little doubt that cholesterol is related to t.rus meta-
bolic disorder in SOHle manner. The exact contribution of chole-
sterol to its etioloey, at the present time, is yet to be 
I'lii 
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clarified. 
~he best ar~ament for tne relationship between chole-
sterol and atherosclerosis is that the sterol is alw~s present 
ill atherosclerotic plaques. The production of atherusclerosis in 
animals by feeding choles~erol has also been interpreted as 
evidence for its role in athero6enesis. The criticism leveled 
a~ainst this type of reasoning is that atherosclerosis in not 
natural for these animals. liowever, this criticism could be 
extended against maD3 other lines of research on human diseases. 
A further implication of cholesterol as an important 
etiological agent in the development of atherosclerosis comes 
from the observations that human atherosclerosis is prominent 
in clinical states accom~anied by hypercholesterolemia. Diabetes 
mellitus, by virtue of its prevalance, is the most important 
of these states. Liebow and llellerstein (134) have compiled data 
froill literature on diabetes. It showed conclusively that a 
definite increase in severity and incidence of atherosclerosis 
accompanies diabetes. The exact cOL'relation between diabetes, 
atherosclerosis and hypercholesterolemia is not clear. Man and 
Peters (150) found that there is no relatiunship betwe~n 
severity of hypercholesterolemia, diabetes and atherosclerosis. 
kabinowitcn (188), on the other hand, found that in Juvenile 
diabetics the severit¥ o£ hypercholesterolemia was proportional 
to the atherosclerotic patients found. Others have co~e to the 
same conclusion re~ard1n~ young diabetics (5b)(115). Iannacone 
and Mollerstrom (112) and Liebo", Helleratein and jailer (135) 
reported that d.iabetic atherosclerosis is related to sex, age, 
and b.Yperteneion, but find .0.0 corL'elation with plasma lipids. 
It wo~ld. seem, then, tnat onl.)" in the cssa o1~ "yount) <1i .oetics 
C~l any connection between serum cnolesterol levels and athero-
sclerosis be defined. ~hls, bowever t still does not exclude the 
fact tllat cholesterol. other than what is f"ound in tue blood, 
can be excluded f"rom consideration in the uevelo~ment of athuro-
sclerosis. 
Rosenthal (201) has sum:,\ed up the bulk 0:1.' evidence 
relat1nt!; cholesterol to atherosclerosis. The conclusions VI'ere 
based on a comparison ot diet t blood pressure, and atheroscle-
rosis from data in a number of ,Populations. lfurther in.dication 
came from the tact that groups su.t1eri~ from malnutrition did 
not have an incidence of atherosclerosis, while well-to-do 
individuals ot the sawe group did. Data obtained during World 
Yvan I Rl1>1 11 .nave shown the efleets ot j:JOor nu.trition on athero-
sclerosis. The 6eneral trend of these reports has been that poor 
\\d..rtime nutrition I.'esulted in decreased incidence of atlleroscle-
rosis in GermaD¥ (2j), Norway (6j), and Russia (114). However t 
even in this data, there were many inconsistancics. In l!lnland t 
for example, the total fat consumption fell continually between 
1937 and 1947. In tne meantime, tne atherosclerosis death rate 
rose from 1'138 to a peak in 1940, droklped until 1943, then rose 
again throllgh l\)4rl (149). Again in Sweden, the total :.t'at intake 
was constant between 1935 and 1939, bliLt the atherosclerotic 
death rate rose during this period. 
Keys (121) has sUGr::.;ested that dietary i'at and not 
cholesterol is to be directly implicated in atherosclerosis. 
Axamination of' dietary data of twenty two co~~tries shows that 
tnis correlation is no better than that for other dietary 
const1tuents (267)(268). It seems, therefore, that thero is no 
connection between the serum cholesterol levels in normal or 
atherosclerotic men and the amount of cholesterol 1n6ested by 
these groups (~5). This conclusion, statistically arrived at, 
could be questioned since it has been found. tha.t prefeedi~ of 
'I 
cholesterol cuts down !a vitro synthes1s of cholesterol by 11ver 'I 
slices (93)(98)(230). 
Lande and Sperry (127) have examined tn. blood chole-
sterol, aort1c 11pid, and the degree of atherosclerosis in a 
number of persons who died. There was an increase of aortic 
11pids, but no increase in blood cholesterol correspondi~ to an 
increase in the degree ot atheroscleros1s. Simi~ar observations 
have been made by Schonheimer (212) and Faber and Lund (81). 
ii' 
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stamlel.' and Katz (222) have shown that prolollt;,ed feedintS of 
small amounts of cholesterol Call lead to severe stherosclerosis 
without correspondiD6 elevations 01 ser~ cholesterol. ~orre­
son (lb6) t on tlH) other hand. t found that the aVel'&t5e cholesterol 
in arteries ot: coronary cases i& four times that; ot' controls t 
and he l'eels that a detini te correlatilJn exists with blood 
cholesteL·ol. 
Recently t the Centl.'al 00mmitee of the Am.I.'ican Heart 
Association released a statement implicatin~ hi~h fat diets and 
high serum cholesterol levels in the proauction of atheroscle-
rosis (50). Paterson (115), however has dis~uted the value of 
this statement. He cites the work of Lande and Sperl:Y (12'7) and 
his own long te:r;'m study on the cOlllparison 01' ante-mortem se.x'Wll 
cholesterol level with tue severity of atherosclerosis post-
mortem in atherosclerotic cases (1'/6). 
Cholesterol-i'ed rabbits rendereu. diabetic by inJection 
of alloxan exbibit a marked lipemia and hypercholesterolemia, 
yet showed a decreased severity 01' atherosclerosis wheu compared i 
witn cholest.erol fed controls ('75)(15d). This alloxan ellect is 
independent of sex, wei~t t tne dura t10n 01' ex.veriment, or the 
form in which cholesterol is fed. The results o~ these experi-
ments have to be interpreted with causion since diabetes ~roduced 
by alloxan cannot be extended to clinical diabetes mellitus found 
in humans. 
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The cholesterol content of the sera of patients on 
cortisone therawy is si~ificantly elevated (3)(7j) and an 
increase in the severity of at~erosclerosis in young cortisone-
treated persons has also been reported (}). Kobernick and 
More (125) found this to be true also of cortisone treated 
rabbits. Cook ~ ~ (61), on the other hand, studied relatively 
tew animals and reported no statistically sibniXicant differe-
nces between the cholesterol and cortisone-sterol groups. The 
relationship between Cholesterol and atherosclerosis, seems then, 
not to be a Simple casual connection. ~~ workers have attempt-
ed to correlate cholesterol with one or another serum fraction 
in the hope ot obtaining a better description of the metabolic 
defect involved. 
Lipids, other than cholesterol, have been known to 
be involved in atherosclerosis by early workers in this 
tield (80)(122). A number of studies have shown that the chole-
sterol/phos~lolipid ratio is elevated in cases of coronary 
disease. AlthOugh the differences in ratios are quite striking, 
so are tnose in cholesterol levels. Oliver and Boyd (173) found 
elevations in cholesterol/phospholipid ratios in coronary artery 
disease in all age groups, however, the differences in plasma 
cholesterol levels are also distinct. One criticism or the 
cholesterol/phospholipid ratio is that the data obtained is 
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always af~er the coronary disease has started, litt~beinb known 
of t,!:.\,e role the chwlges may p.Lay in initiatinb the disease. 
A refinement of tlle cholesterol/!>ho6pholi~id rela-
tionship has involved the determination of these ra'tios in the 
lipoprotein fractions of' the blood (205). The findiIltS in normal 
patients and in patients with atherosclerosis indicate a shift 
of' cholesterol from the alpha to the beta livoprotein with 
advancin6 ~e and in certain hypercholesterolemic states. A 
cooperative s:budy by the Advisory Council of the NatioLlal Heart 
Association has studied both serum cholesterol and lipo9rotein 
values in a lar~e number of cases over a laub period of time. 
The majority opinion was that the lipoprotein measurament pre-
sented no advantaee over cholesterol analysis in characterizatio~ 
of persons prone to develop coronary heart disease (16j). 
~ceSB cholesterol or altered cholesterol metabolism 
is alw~s present in the active stages of human atherosclerosis. 
it can be identified in t.be athel.'osclerotic lesions and can be 
extracted. from them. Human arterial lesions can be produced 
experimentally by its use with more exactness than the lesions 
of many human infections can be produ.ced by the introduction 
into susceptible animals of their reco~zed. causal agents. 
It can be identified in and extracted from the experimental 
lesions. Cholesterol t tllen, has to be conceded a. role in the 
" 
, " 
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etiology of atherosclerosis. Whatever side one takes in the mw~ 
controversies within the field of atherosclerosis, all agree 
that a general drop in serum cholesterol levels should be 
beneficial. 
It was stated before that atherosclerosis is very 
prominent in states accompanied by 4ypercholesterolemia. One 
o~ these states, diabetes mellitus, is statistically the most 
important clinical entity associated with disturbed lipid meta-
bolism and a h3percholesterolemic ten~enc3. The mass of evidence 
demonstratin~ a marked incidence and severity of atherosclerosis 
in diabetes is incontrovertible. Provided they have the disease 
long enou~, diabetics will almost invariably be atherosclerotic. 
warren (245) has found onlJ four patients free of atherosclerosis 
among 484 autopsied cases with diabetes for five years or lonber. 
This universality of atherosclerosis in diabetes is true for 
young and old, female or male. Joslin (119) has stressed that 
the frequency and severity of atherosclerosis in diabetes is 
correlated with long standin6 uncontrolled ~lycosuria and 
h3per~lycemia, with concominant hy~erlipetu1a and h3~erchole-
sterolemia. 
With the discovery of insulin and the oral hypo-
glycemic agents, the primary disturbance of diabetes mellitus, 
hyperglycemia, has been controlled. There is, however, still a 
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question as to whether the accomp&~i~ b3percholesterolemia 
is reduced by these agents. It would be ver;t beneficial if the 
h,ypogl.1cemic compounds controlled bot.h the e,lucose and chole-
sterol disorders. If the agents used for controllin~ diabetes 
do not at tHe same time control the cholesterol of the body, 
only one metabolic disorder is remedied. What is more important 
is that the cumpounds, although decreasing the blood glucose 
level, do not increase the cholesterol level. The net effect 
would be that of controlling one metabolic disorder while 
encouraging the deveLopment of another metabolic disorder, 
atherosclerosis. 
The effect of the hypo~lycemic compounds on the chole-
sterol levels of the blood has not been studied very extensively. 
The few results that are available are at variance with each 
other. Carbutamide, an early hypoblycemic compound no longer 
in use, was found to cause hypercholesterolemia (105). Tolbu-
tamide has been variously reported. to increase or have no e1:fect 
on the Cholesterol level of the blood (48). Recently tolbutamide 
has been reported to decrease the beta-lipoprotein fraction 
while havin6 no effect on cholesterol level (101). However, 
this result was obtained with persons who had normal values £or 
blood cholesterol. In the few instwlces where the patients did 
have a higher t.l:lan normal cholesterol, the blood levels weL'e 
slightly reduced (101). There has been no definite report as 
to the effect of the hypoglycemic cUDl,Pounds on blovd cnolesterol 
or on the biosJnthesis of cholesterol, with the exception of 
insulin, which does lower the blood cholesterol (l?l). 
Since many investigators believe that if the bio-
synthesis of cholesterol is controlled, the blood cholesterol 
will also be controlled (93)(98)(231), the investi~ation 
described in this thesis will deal with the effect of hypogly-
cemic compounds: tolbutamide, ~henetr~lbie~anide, chlorpropamide, 
and metahexamide on cholesterol biosynthesis !!!. vitro. A com-
parison of these C0D190unds will be made with that of insulin. 
If there is an effect of these com~ounds on the biosynthesis 
of cholesterol t the elucidation of tl:l.e site of action will be 
attempted. 
Procaine hydrochloride, althout)h not a hypoglycemic 
compound, will be included in the study since it does lower 
both the blood pressu.re and tIle cholestdrol levels of the blood. 
The m.aterials and methods used in the investi~ation 
of the effect of hypoglycemic COJ:lpowlds and ,a;>rocaine on chole-
sterol biosynthesis are described in this cha,t>ter. 
MAl'ERIAl1) 
~c~bator-Shaker: 
The incubator-shaker used in tIle invest.ibation was 
sp6ciaJ.ly constructed by Elmac En~ineerint5 Comjllin.Y, ChicliuO, 
Illinois. The shaker has a variable speed from 2j to 160 cycles 
'per minute ~ld a variable stroke of a quarter to two inches. 
The temperature is controlled by a mercury relay haviD6 an 
accuracy of + 0.20 C from the set temperature. It also has a 
water-sealed gable cover throu~h which any desired atmospnere 
can be introduced. The incubation tray has places for sixty-six 
25 or 50 mI. erlenmeyer flasks. 
Animals: 
The animals selected for use in tnese experiments were 
Sprabue-Dawley female rats obtained from Abrams Small Stock 
Breeders, Ghica~o, Illinois. 'rhe rats, wei ..... hing 8.,ih?roximately 
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200 grams, were kept on a regular stock diet. 8acrificin~ was 
done by decapitation. 
Apparatus used in the preparation of tissue homogenates: 
The rat livers were homogenized in a homogenizer of 
the Potter-Elvehjem type which consisted of a smooth glass tube 
and stainless steel pestle, with a gap of approximately 0.5 mm 
between the pestle and the tube. The neccessary enzymes for 
the biosynthesis of cholesterol were prepared by using a Spinco 
Ultracentrifuge (Beckman Instruments Inc., Spinco Division, 
Belmont, Califo~nia). 
Hypoglycemic compounds: 
Tolbutamide (lot # CJO 11,584-2) and Metahexamide 
(lot # CJO 12,860) was supplied by The Upjohn Company, Kalamazoo t 
Michigan. Phenethylbiguanide (lot # 21) was supplied by U.S. 
Vitamin Corporation, New York, New York. Chlorpropamide (lot 
# 03-422-02EPD) was supplied by Charles Pfizer and Company, Inc., 
New York, New York. Insulin (Iletin, 40 U.S.P. units/ml with 
an expiration date of January, 1962) was supplied by Eli Lilly 
and Company, Indianapolis, Indiana. The insulin was stored in 
the refrigirator at 4°C. until ready for use in the experiments. 
Coenzymes: 
Diphosphopyridine nucleotide (DPN, AR, lot # 50B7l3), 
triphosphopyridine nucleotide (TPN, AR, lot # llB745) and 
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adenosine triphosphate (ATP, AR, lot # 50B713) were obtained 
from Sigma Chemical Company, St. Louis, Missouri. The cofactors 
were kept under refrigiration at -10°0., until ready for use in 
the incubation mixture. 
Acetate-l-C14 : 
Sodium salt of acetate-l-C14 was obtained from Volk 
Radio-Chemical Company, Skokie, Illinois. The original specific 
activity of acetate, 7.0 mc/mM, was diluted to 1 uc/20 uM by the 
use of unlabeled sodium acetate (AR, lot # 90628) obtained from 
Baker and Adams Chemical Company, East Rutheford, New Jersey. 
The method of preparation was a carbonation of methyl Grignard 
reagent and then hydrolysis. The acetic acid WclS isolated by 
steam distillation, titrated with standard NaOH and evaporated 
to dryness under vacuum. The radiochemical purity of the pre-
paration was tested by carrier dilution analysis as sodium 
acetate and silver acetate, and one dimensional chromatography 
and radiautography of ammonium salt with n-butanol saturated 
with aqueous 1.5 M NH3• The minimum purity, as evidenced by the 
above criteria was found to be 98 to J9 per cent pure. The 
radioassay of the acetate-l-C14 was done by combustion to CO2 
and comparisoll with HBS standard in an ioni zatioll chamber, 
100 ± 5 per cent. 
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FreR!£ation of liver ho.oienates: 
Livers were obtained from rats weighing a~vroximately 
200 grams wbich were sacrificed by decapitation. The livers were 
blotted, weighed. as wet weight, and ground gently at 100 rv. for 
one to two minutes with 1.25 volumes of the Standard Buffer. 
The preparation ot the buffer is described in the Appendix, 
Part I. Unbroken cells and tissue debris were eliminated b¥ 
centrifugation at ?00xg for 15 ainutes in a Spinco Ultracentri-
tuge. The entire process was carried out at OOC. The su~er­
natant homogenate obtained was used as the source of enzymes 
for the biosynthesis of cholesterol from acetate-l-C14 • 
The incubation mixture: 
Each incubation vessel contained 0.5 al. of rat liver 
homogenate (approximately 800 1It>. of liver), the h,ypo~lycemic 
compound or procaine in the specified amount, one al. of 
Standard Buffer solution, and one ml. of substrate solution. 
The substrate solution contained 1.8 micromoles of diph089ho-
pyridine nucleotide, 1.8 .1cromo1es of triphosphopyrldine 
nucleotide, ~.~ micromoles of adenosine tri9hosphate, and 0.5 
microcurie of acetate-l-Cl4 (as assayed by Tracerlab 60-16 
Windowless Gas Flow Counter) made up w1 th Wllabeled sodium 
acetate to a total of 20 mlcromoles of acetate 1n each lncubatl0 
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mixture. 
Constancy of the liver homogenates: 
In order to test the constancy of tne liver homo~e­
nates from preparation to preparation, the total cholestervl 
of the homogenate was determined in each rat liver homobenate 
tnat was prepared. Uholesterol analysis was done by the method 
of Hermann (107). Before this procedure was adopted, two other 
procedures were tried. One teChnique was based on a mOdified 
ti~erry and ~ebb (221) cholesterol determination. The other 
method de vended on a color formation of Cholesterol with FeS04 
in acetic acid (131). Both methods proved less reproducible 
and more cumbersome than the procedure of Hermann (107). 
The color reagent for this method is made from a ten 
per cent li'eCL3• 6H20 in redistilled acetic acid which is mixea 
with 150 ml. of re.gent grade H2S04 and made up to one liter. 
The procedure for the determination of cholesterol in tissue 
was a& follows. The Cholesterol was saponi1'ied and extracted 
as described later in the chapter. A suitable aliq,uot of t,ile 
petrolew:l et,her extract was pla.ced in colol.'imeter tubes and 
tue ether evaporated to dryness. To tne dr~ resisue b ml. of 
tllacial acetic acid. was add.ed and then 4 mI. of tne color 
rea6ent was forcefull~ introduced directly into the ~lacial 
acetic acid by a 10 ml. hJ~erdermic syrin~e. ThoroUbh mixinb 
i'I' I'
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was insured. ~'he tubes were ali.ov.ed to cool to roum tem~erature 
and the color density was read or .. a Klett colorimeter using 
I~ 5b filter. The color is stable for at least two hours. 
A standard curve, shown in F1eure I, is pr~pared bJ 
addint,; from 0.1 to 1.0 Illl of' 20 mb% standard cholee tarol solu-
tion 1n glacial acetic acid. mou6h 61acial acetic acid is 
added to make total vulwne 6 rul. Thl! color is then developed 
as stated before. Prior to preparation of tn.e standard stock 
solution, the cholesterol was purif'ied, as f'0110w8: I,:;) f:!)rams 01' 
cholesterol (obtained from Eastman Chemical ?roducts, Inc., 
t;kokie, Illinois) was dissolved in 130 ml. of boiliJlltS 95% 
ethanol. The solution was then filtered and cooled slo~ly at 
about 50 0. 'rhe white crystals of choleste1.:ol which were formed 
were removed by filtrationthroug.h Whatman if 42 filter paper. 
'l'ht: recrystallized cholesterol was dried in a vacuum desiccator. 
The purity of tLe recrystallized cholesterol was ascertained 
by the sharpness ot the meltin6 point o£ the crystalS. The 
standard solution was prepared fresh every 2 to ~ weexs. 
The constancy of the liver homo~enate vreparations 
is shown in Table III. The cholesterol content of six dif:f'erent 
rat liver homObenates difl'ered only by 0.4 ~7u. It followeu, 
therefore, that t,be h01Jlogenates prepared from ex~eriment to 
experiment were the same. 
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TABLl!; III 
CONSTANCY OF LIViSH .tiOml()G~N ATES 
Expt. Klett Heading Cholesterol Average 
mg/& keadin& 
1 144 12.b 
136 11.,/ 
140 12.5 12.2 
2 135 11.6 
146 ; 12.d 
144 12.6 12.3 
3 138 12.1 
140 12.) 
135 11.0 1;:.1 
4 145 12.3 
143 12., 
142 12.4 12.4 
5 150 13.1 
137 11.j 
13~ 11.0 12.2 
b 138 12.1 
1" 11.5 
139 12.4 12.0 
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Incubation: 
Studies on the incorporation ot acetate-l-C14 into 
the non-saponifiable lipid were carried out aerobically in the 
Elmac metabolic shaker at }7°C. The oxygen was introduced into 
the incubation vessels and used for flushing the C1402 that .as 
produced was delivered by ~ series of tyson tubing into each 
individual vessel. The vessels, 25 al. erlenmeyer flasks~ were 
sealed by stoppers that had an inlet and an outlet to which the 
ty~on tubins could be attached. The 0~402 was collected into 
pyrex test tubes containi~ 10 per cent KOH solution. Atter a 
two .nour 1llcubation period, the reactions were stopped by the 
ad~ition of 3 ml. of 15% KOB in 50% ethanol to each incubation 
vessel followed by heati~ for 10 minutes at 37°0. 
Isolation and extraction of non-saRonifiable liRids ana chole-
sterol: 
The partiall,- saponified reaction mixtures were trans-
ferred to a 25 al., screw-capped culture tubes, and the reaction 
vessel was rinsed with 3 al. of the alcoholic KOB solution and 
added to the contents ot the culture tubes. Saponification was 
completed by heating the titShtly capped tubes in water bath at 
75-800 C., for 60 minutes. The saponified reaction mixtures were 
extracted four times with 10 ml. portiolls of li~ht petroleum 
ether (30-60°0 boiling fraction). This solutiun contains the 
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total non-saponifiable lipid. It is composed of squalene, chole-
sterol, a~l cholesterol intermediates between squalene and 
cholesterol, and. other non-saponifiable lipids. 
In experiments where only the cholesterol was deter-
mined, the petroleum ether was evaporated to dryness iL a heavy 
duty centrifuge tube. The residue was dissolved in 3 mI. of 
acetone-ethanol (1:1 volume for volume), an~ 1.0 mg. of ~arrier 
cholesterol in 0.5 JUl. of ethanol was adeled to this solution. 
The ;-beta-hydroxy sterols were precipitated by the addition 
of ? ml. of 0.5% digitonin (AR, lot # 51}480, obtained from 
Merck, Sharp and Dohme Company) in !J~ ethanol. After standine; 
at room temperature for 16 hours, the digitollide precipitate 
was recovered by centrifugation, washed once with 90% ethanol, 
once with acetone, once with acetone-ether (1:2, volume for 
vo~ume), and tinally with petroleum ether. 
In experiments where both the cholesterol and the 
total non-saponifiable lipid were determined, on13 a suitable 
aliquot of the petroleum ether extract was used :1'01: Cholesterol 
determination. 
Measurement of radioactivity: 
014°2 was precivitated as the barium salt. The method 
of recovery of 014°2 as BaC1403 depends on the nature of the 
information desired. If tHe interest lies in a y,uantitative 
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yield, the best procedure would be to collect aLU titrate the 
carbonate to bicarbonate; follo~ ... in~ which it may be precipitdted 
as bariUll;, carbonate o.r the addit.ion of bariwn ion. If one, 
however, is interested in only a semiquantitative ~ield or 
precise specific activity, the C1402 can be absorbed by an alka-
line solution and then precij,)itated by BaC12 • Since the author 
was interested in the specific activity of the 014°2 obtained 
from the incubation, the latter method was chosen. A suitable 
aliquot, usually one milliliter of a total vol~e of 5 mI., was 
taken and precipitated by a l~& solution of BaG12 • The Bacl4o, 
was then plated out Qn a pre-weighed # 42 Whatm.an filter paper. 
After the weit;5ht of the preci'pitate was noted, the filter 'pclper 
14 2 
with BaC °3, having a surface area of 2.84 em of plate4 mate-
rial, was ~laced Lnto a planchet and the C14 activity waS measu-
red with a Tracerlab 8C-16 iilldowless ]'low A.ssembl'y attached to 
a Tracerlab Autoscaler (Tracerlab, Inc., Bos~on , Mass). All 
readings weL'e corrected for background and for self-absorption. 
The measurable activit~, It differs from the actual 
activ·',ty, lot becal.1se of self absorption of' the sWIlvle. rrhe 
amount of self-absorption is given by the quotient 1/10 (5): 
I 1 -uh 
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where u is the a'baorption coefi'icient, and h is mg/cm2 of the 
~lated. material. The absorption coe1'.:r."icient for (;1.1+ in BaG03 
has been eX.j,>eriItlentall,y found to have an average value of 
0.29 (2& .. ). Using the self-absorpliion coef'ficient, the e'1uation 
gi ven OIl the previous page is reproduced in l!'it..:ure II &lld is 
called the sclf'-absor,1Jtion curve. The curve was used to make 
self-absorption coz'~"ectiolls for all sam.~les of Bac14()3. 
The 3-beta-hydroxy sterol dibitonide was measured the 
14 same w~ as BaC 03. Here, again, the problem of self-absorption 
had to be considered. £\.lthout;;h a varioety of substances have 
self-absorption curves suf.ticientl'y similar to that of Bao140 3 
to permit the use of the latter, a search of literature did not 
provide any information as to the self-absorption of cholesterol 
digitonlde. The self-absorption curve f'or cholestt-:rol dieitonide t 
therefore, was determined. 
Cholesterol-C14 obtained from several incubations of 
acetate-l-C14 with rat liver homogenates was pooled and 5.0 
of carrier cholesterol wa!:J added for ever'y incubation vessel. 
'L'lle final solution contained 42.3 mg. 01' cholesterol as deter-
mined colorimetric all" by the method 'previously described. The 
Cholosterol-C14 solution was made up to a volwae so it contained 
2 mb of cholesterol per milliliter of solution. Six dif1erent 
ali'iuots (1,2,3,4,5, and 6 ml.) were taken and the cholestez'ol-
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C14 in each aliquot was precipitated by digitonin, ~lated and 
cowlted as previously described. The results obtained are shown 
in Table IV. The self-absorption correction curve (ldbure Ill) 
obtained from the results in Table IV were used to make self-
absorption corrections for the cholesterol dieitonide. A detaile 
,tirocedure for the construction 01' the self-absorption curve for 
cholesterol digitonide appears in the Appendix, Part I. 
14 ]'or tue determination of the Cacti vi toY of the total 
non-saponifiable fraction, suitable ali~uots ( 1 to 2 mI.) of 
the petrole~n ether extract were measured in a Packard Tri-Carb 
Liquid Bcintillation Spectrometer (Packard Instrument Company, 
Inc., Chicago, Illinois). ;'l1aximum efficiency was obtained with 
a photomultiplier tube voltage of 1020 v. and a discriminator 
setting of 10 to 100 v. li'or all countint!J, who'ther gas flow or 
SCintillation, a sui'ficient number of counts wao taken to reduce 
the statistical error of cOWltinc to less than 5 per cent. 
The RreRaration of the scintillation solution: 
The composition of the li~uid scintillator which met 
the criteria of tJ.1e hit;,hest counting e11iciancy, as sUt;;u . ;ested by 
Br&7 (42), was as follows: 60 gm of naphthaline (recrystallized 
from alcohol, lot # NX 5) manufactured by ~atheson, Coleman, and 
Bell Co., East Rutheford, New Jersey and obtained from Chica~o 
Apparatus Co., Chicago, Illinois; 4 gm. of toluene-2,5,-dipheD¥1-
·1 :' 
Weight of 
cholesterol 
m.g. 
2 
4 
8 
10 
12 
'lABLE IV 
Cholesterol 
digiton1de 
mg. 
8.4 
16. '/ 
50.8 
'75 
i' 
'.1.1" II; 
a/Wme; 
1050 
705 
11.8 
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oxazole (lJR), lot;;' 21002) and 0.2 gIa. of l.4-d.i-2-(5-p.uell,yl-
oxazoyl)-benzene (POPOP, Scintillation Grade, lot d 2023) 
obtained from J?ackard Ins·trument Co., Inc., Chicago, Illinois; 
100 ml. ot absolute methanol and. 20 ml. of etl~lene glycol 
dissolved in p-dioxane (Spectroquality Reagent, lot # DX 20>:J5) 
manufactured by Matheson, Coleman and Bell Co., and obtained 
from Chicago Apparatus Co., Chicago, Illinois, to make one 
liter. 
Ten milLiliters of this scintillation solution was 
8.uded. to a counting vial containine; one milliliter 01' the active 
petroleum etheL' solution that was to be deteI.'milled. 
THE EFj'ECT OF HYJ?OGLYCEf4IC C0i!4R>UNDS AND PHOCAINl!; ON 
CHOLESTEROL BIUSlNTHESIS 
The mechanism b7 wbich the ar31sul~onylureas exert 
their bypog17cemic action is still dis~uted. Though the 
compounds are at best poorly effective in the absence of fun-
ctional pancreatic beta-cella, it has ~een observed that these 
compounds affect other metabolic 94thways without the mediation 
of insulin. Since cholesterol is thought to be associated with 
atherosclerosis and since ATpercholesterolemia is prevalent in 
diabetes mellitus, an investigation was undertaken to study the 
effect of these compounds on cholesterol biosynthesis ~ vitro. 
FACTORS AJ'FECTDG THE RATE OF BIOBI!iTHlSSIS 0.1 CHOLJjSTEROL 
The factors affecting the rate of incor~oration of 
acetate-l-C14 into cholesterol have been studied by Frantz and 
Bucher (91). Since it haa a direct relationship to the problem 
at hand, a discu8sion of theee factors would see. in order. By 
omaission of i.1.ifi'erent coa.ponents. j'rantz and. Bucher (91) 
obtained a maximum incorporation of acetate in the presence of 
MgC12 , DPN. and nicotinamide. In the absence of added MgC12 or 
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nicotinamide, the activity ot tue synthesized cholesterol was 
very low, and in the absence ot both nicotinamide and DPN it 
was reduced to near zero. In tne Vresence of nicotinamide, 
ommiasion of supplementary DPN dro~ped the incorporation of 
acetate-l-Cl4 to approximately 25 to 50 per cent ot the maximum 
obtained with the complete system. 
ThB neceesaity for Ms~+ and Da~ tollows trom the fact 
that both are needed in the biosynthesis of cholesterol. Mg++ 
1s neceeseary for the activation of most enzymes from mevalonic 
acid to squalene formation. DPH, in the reduced form (DPNH) 
probably serves as a reducing agent in the conversion of de-
hydrosqualene to squalene. The reason that these two seem to be 
lackin6 in the liver homogenate is probably because they are 
lost in the preparative procedure. Bucher and li'rantz (91) found 
that the maximum incorporation of acetate into cholesterol occurs 
when the concentration of DPN is 0.0008 M and the concentration 
of MgCl2 is 0.0048 M. 
The need tDr the presence of nicotinamide seem. to be 
to protect DP.NB. from being .b.ydro17zed. back to DPN. The Dlax1.mp 
Dlolarity of nicotinamide for the ~ vitro synthesis of chole-
sterol was found to be 0.05 M. 
Since the catalysts in the reactions are enzymes, the 
effect of pH is a great factor. It was recognized that the 
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but fer strength empl07ed in the experiments was inadequate to 
maintain the pH ot the concentrated homogenates at a constant 
level. The optimal ~H range ap~ears to lie between 6.8 and 7.2. 
Because ot the· drop during incubation, the maximal incorpora-
tion in two hours was obtained when the pH of the but fer was 
ini tially 7.4· to '7. o. The et't.eet ot veu~yifj,b the pH of the in-
c·v.bation mixtures is sho¥;u in Fit,ure IV. The initial and tinal 
pH of the inCUbation mixtures axe shown in the ii6ure. 
The amount of tissue present in the incubation 
mixture is proportional to the activity obtained in cholesterol. 
In all instances, hit)her activities are obtained at high tissue 
concentrations, and ne61igible ~ctivity in dilute 'pr~'parations, 
but the concentration at which the synthesis ~as maximal varied. 
The incorporation of acetate-l-Cl4 into sterol i8 aleo propor-
tional to the time of incubation. After a slibht del~, the rate 
was nearly linear for the first two hours and did Lot deviate 
aven after four hours. 
The effect of increasing the acetate concentration 
upon the amount of cholesterol s¥ntheslaed is shown in Fi~ure v. 
The incorporation curve reached a plateau at an acetate con-
centration of 8 to 12 micro.oles, whereas the allOunt oxidized 
continued to rise. In teras of the available acetate present, 
20 to 25 per cent was oxidized to CO2 in the presence of 8 micro-
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FIGURE IV 
EF" ... .biCT OF VARIED pH UPON THE INCORPORATION 0]' ACh'TAT& 
CARBOXYL CARBON INTO CHOLESTEROL 
The initial 'pH 01' the incubation mixture is given in parentaaes. 
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moles of acetate, whereas only 12 per cent was oxidized when 
the acetate concentration reached 20 micromoles. 
Po~jak !! ~ (185) have snown ex~eri~ent~lly that 
not only DEN, but TrN and AT~ as well are needed for the 
max1~~ incor~oration of acetate-l-Ol4 into ellolesterol. 
The final cv.uc~utl.·atil.illS of substrate and C01'actors, as SUbbestec 
0.1 li'rantz and Buchel.' 's (91) and Po..,Jak's (lB5) data., was chosen 
to be 1.8 micromoles of DEN, 3.j micromvles of ATP, 1.8 micro-
moles of TPl~, 20.0 lIl1cromoles of acetate ill a ,PL.os,tihate buffer 
(~ll 7. /{) conts.inin~ 75 micromolC8 of nicotinamide (C.O;; .itt'), 
12 micromoles of lIigC12 (0.0048 M) and 200 micI'omoles of phos-
phate (0.08 1\1). 
EFlt"'ECT OF TOLBUTAJAIDE ON CHOLliSTEROL BIOSYN'!HESIS 
Incubations were made with rat liver homo~enates, 
acetate-l-c14, and tolbutamide in the presence of ATP, DPN, TP.N, 
and Mg++ in a phosphate but':fer (pH 7.4) tor two hours at }?oc. 
After the incubation, tile 3-beta hydroxy sterols were isolated 
and counted as previously d.escribed. 
The results in Table V indicate that tolbutamide 
inhibited the incorporation of acetate-l-C14 into sterol at the 
very low amount ot 0.05 micromoles. The maximal inhibItion was 
between 4 and 20 micromoles. The specific activity is expressed 
TABLE V 
EFFECT OF TOLBUTAMIDE ON CHOLESTEROL BIOSlNTHESIS 
PART I 
ConcentratIon 
of tolbutaa1de 
in micromoles 
None 
2.0 
4.0 
20.C 
S~ecItlc ActivIty 
of cholesterol 
; C/jA/g 
180 
1~5 
124 
92 
9 
84 
0.1 microcur1es of acetate-l-l;14 was used in each incubation 
vessel. 
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in elM! mg of cholesterol and was obtained by multi~lyi~ c/M/mg 
of cboles~erol digitonide by the gravimetric factor 4.18. 
In order to find the relationship between the con-
centration of tolbutamide and the inhibition of cholesterol 
biosynthesis, a study was made ot the effect of the concentra-
tion of tolbut.a.mide on the incor,Poration of acetate-l-C14 into 
sterol. Ta'b1e VI shows that the in.h1b1 t10n is proportional 
to the amount ot tolbutamide present in the incubation mixture. 
The maximum inhibition was obtained when the amount of tolbu-
tamide was between 12 and 16 micromoles. Beyond this range the 
biosynthesis of cholesterol was almost zero. 
EJ'~'ECT Oli PHEliA~HY.LBIGUAl .. ID.E ON CHO~GTEROJ:' BIOS:!.NTHESIS 
The hypoglycemic compound that was studied next was 
phenethylbie;uan1de. This compound is difierent from the aryl-
sulfonylureas in that it produces its ily,Poglycemic ei'fect 
without the mediation of insulin. It is active 1n alloxan-
diabetic animals and increases gl~cose uptake by isolated 
tissues, while the arylsulfonylureas do not. 
Although the oom~ound is diiierent in its structu~. 
and hypoglycemic action from the arylsulfon..rlureas,tlle ei'1.ect 
of phenethylbiguan1de on cholesterol biosy~thesis is about the 
same. Table VII ind.icates that when the amount of 'phenethyl-
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TABLE VI 
EF1ECT 0]' TOLBUTAMIDE ON CHOLUSTEHOL BI0SI~THls8IS 
];JAR'!' II 
concentration 
ot tolbutamide 
in micromoles 
None 
4 
8 
12 
16 
20 
Sgecific Activity 
ot cholesterol 
elM/rAt!; 
1220 
151 
11 
46 
45 
% Inhibition 
58.1 
88.0 
94.2 
96.2 
')6.2 
1.0 microcurie. of acetate-l-C14 was used in each incubation 
vessel. 
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TABLE VII 
EFld,;CT OF p~l!.'frHlLBIGUANIDE ON CHOl.J!;STbatOL BIUt~I""THESIS 
Concentration 
of PUG 
in micromoles 
None 
2 
6 
8 
10 
Speciric Activity 
of cholesterol 
c/M/mg 
1610 
1340 
788 
455 
~2 
~~ 
" Il1hib1tion 
16.8 
51.0 
71.7 
78.8 
98.0 
1.0 microcuries of acetate-l-C14 was used in eaoh incubation 
vessel. 
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bi~uanide was ten micromoles, the com~ound almost completely 
inhibited the inC01"l>orat1on ot acetate-l-C14 into 8'tEtrol. The 
effect of the amount of phenethylbi~uan1de in the incubation 
mixture was again pro,portional to 'I.;he decrease in radioactivity 
in the sterol di~iton1de. The degree of inh1bi~ion of different 
amounts of 'pheneth31bi.~ide on the biosynthesis of cholesterol 
compares favorably with that of tolbutamide as shown by 
Fi..,ure VI. 
Elil!JX;T Oi 'pH ON THE INHIBITION 
In order to be certain that tne iI~ibitory erfect of 
tolbutamide and phenethylb1b uanide, and any subsequent effect 
of other compounds that were investigated was not due to pH 
cbant5e. of the substrate solution due to t .... e different WDOu.nts 
of the comj,lounde used, pH measurementa were made on the diffe-
rent solutions. The pH of these solutions was measured by a 
Beckman.glase electrode pH meter, Model G. Table VIII shows 
that the buf'f'ering capacity of the standard .vhosphate buffer 
was adequ,te to maintain the pH after the addi'tioll of tue 
different concentrations ot hypog17cemic compounds or procaine. 
A consideration of the effect of tile dif.ferent amounts of the 
inh.i'bitors on the pH of the incubation mixtures is also in 
order. After a two hour incubation time, the pH ot the homoSe-
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TABLE VIII 
pH OF SUBSTRATE BOLlYl'IONS AND 11,CUBATluN f41XTURli2 
Solution 
Tolbutamide 
Chlorpropamide 
Metahexam1de 
Phenethylbiguanide 
Insulin 
Procaine 
pH of solution 
7.40 
7.40 
7.40 
7.34-
7.40 
pH of incubation 
mixture after 
incubation 
6.95 
6.98 
6.9~ 
6.89 
7.00 
The amount of procaine was 50 micromoles, the amount of insulin 
was 10 U.S.F. units. All other compounds were used ill the 
amount of 10 LUicl:omoles. 
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nates was measured a8 before. The results shown in Table VIrI 
indicate that the pH of the incubation mixtures atter a two 
hour incubation was still in the ovttaal pH ranse (6.8 - 7.2) 
required tor the maximal biosynthesis of cholesterol from 
acetate-l-Cl4 • fhe inhibitory eftect of tolb~tam1de and phen-
ethylbiguanide, and a:D.¥ subsequent eli'ect .. ! other compounds on 
the biosynthesis of cholesterol, therefore, was due only to the 
presence of the compound. in the incubation mixtures and not to 
&nT pH changes which might be associated with the different 
amounts of the inhibitors. 
DIGITONIN AS THE .PllliCIPITATING AGEBT liOl{ CHOJ~Tb;hOL 
The use of digitonin in the precipitation of chole-
sterol might be questioned, since it is not specific for chole-
sterol alone. It preci9itatea all '-beta hydroxy st~rol present 
in the mixture. j'rantz and Bucher (91), whose incubation 
procedures were followed, tested the sterol fraction recovered 
as disitonide for identity and purity. The procedures followed 
to test the hypotheSiS that the radiactivity was present as 
cholesterol was (a) fractional crystallization, (b) pass8&e 
through the acetate, (c) passage throv.gh the dibromlde, and 
(d) a solubility curve. They found that the sterol preciv1tated 
by di~itonlde from the incubation mixtures contained 97 per 
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cent cholesterol and" per cent imjlurities and contained no 
higher counting companions. Since the incubation procedures 
that were followed were the same as that of Frantz and Bucher 
(91), the purity of the cholesterol obtained from the incubation 
mixtures was assumed to be the saae as obtained by thea. The 
inhibitory effect, therefore, is on cholesterol biosynthesiS 
and not on any other 3-beta hydroxy sterols. 
Karab., McLaU&h1in and Ri.~e1 (120) have described 
a procedure of precipitation ot chole,terol br replacement of 
digitonin by the g~coa1de tomatin as the precipitating asent. 
The new reagent is more s~ecitlc tor cholesterol than is 
disitonin. While the gl1coside does not possess absolute 
speci.:Cicit;y, the sterol isolated from mce 15 minutes a1'ter 
methyl labeled tritium acetate administration is free of hisher 
counting com.panions. j'or amounts ot cholesterol 0.50 milligrams 
or greater, quantitative precipitation takes place in les8 than 
one hour at room temperature as compared with 16 hours tor 
digitonin precipitation. Although tomatin would be a better 
reagent to use, the preCipitates obtained could not be verr 
easily plated for rounting. They were uneven and very fl~. 
Kabara et ale (120) also towld that the saponification of 
--
esterified cholesterol was a critical step since too much alkali 
decreases the ac~uracy of the cholesterol assay. The molarity 
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of the KOH used in the hydrolysis of cholesterol esters by the 
author was quite high, and therefore, the recovery of cb.olesterol 
as the tomatin derivative would be very low. Because of this, 
the use ot tomattn as the precipitati~ reagent tor Cholesterol 
was abandoned and all precipitations were made with digitonin. 
In an attempt to localize the site of' action of the 
hypo~l¥ce~c compounds 1n the inhibition of cholesterol bio-
s.Y.tI.tLtesis, a study was made ot tile non-saponi1"iable lipid 
fraction after incubation with tolbutamide. Although no one, as 
yet, elucidated the completo nature ot this non-saponifia"ble 
fraction, it i8 known that it contains squalene, post-squalene, 
intermediates, and cholesterol. The data, shown in Table IX, 
indicates that tolbutamide in concentrations of 0.05 to 20 
micromoles inhil<lted the incorporation of acetate-I-CI4 into the 
non-saponifiable lipid. Also, the magnitude of the inhibition is 
clearly dependent on the concentration of tolbut.amide. The per-
Ce.i:ltage of inhibition of the formation of' non-s&.p0nifiable lipid 
sugbested an 1nterruption ot the biosynthesis of cholesterol at 
an earls stage in the reaction sequence. 
In order to obtain a clearer picture of this inhibition 
a study was made of the distribution of radioactivit3 between 
.1 
TAB1.& IX 
.K]'FECT OF TOLBUTAMIDE ON NO.N-SAR)NIFIAIU...E; LIPID 
Concentration 
of tolbutamide 
in micromole. 
Bone 
0.05 
2.0 
4.0 
20.0 
Uon-s~on1f1able 
lipid 
total CIM 
5,080 
4,000 
,,240 
2,870 
1,690 
0.1 microcuries of acetate-l-Cl4 was used in each incubation 
vessel. 
95 
the di~itonide precipitable sterols and the other components 
of the non-saponifiable lipid fraction. Tolbutamide, phenethyl-
bit:,uanide, chlorpropamide, aetaheX8Jllide ( in the amounts of 10 
micromoles) and insulin (0.1, 2.0 and 10.0 U.S.P. usits) were 
incubated with rat liver homogenates and acetate-l-Cl4 • After 
the Incubation, the Cholesterol and the non-saJ:i0n11iable lipid 
weI'e isolated and the acti vi ty determined. Table X shows that 
both the digitonide precipitable cholesterol and the total non-
saponifiable 11pid were inhibited b¥ ~ll compounds, but not to 
the same extent. The arylsultonTlurea compounds had a lesser 
effect than either phenetbylbibuanide or insulin on the incor-
poration ot acetate-l-C14 into the non-saponifiable lipid. 
Furthermore, chlorpropamide aad metahexam1de had a lesser effect 
on the biosynthesis ot cholesterol than the other compounds that 
were tested. Insulin, even in the very low amount ot 0.1 u.s.P. 
units completely inhibited the biosynthesis of cholesterol. 
lioreover, 10 U.S.P. units of insulin had the same eflect on the 
formation of the non-saponifiable lipid as phenetb¥lb1suanide. 
When the amount of insulin was reduced to 2.0 and 0.1 U.s.P. 
unita, the formation of tne non-8aponi~iable lipid was increased, 
although it was never h1~e~ than the nOll-8apolll~iable lipid 
obtained when the arylsultoD¥lureaa were used. 
In order to obtain tiJ.e etrect oi' the inhibition of 
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TABLA X 
DliEC';r OF Hl.POGLYC.haUC AGEHTS ON liUl,-SA?VNIJfLABLil; LIPID 
None 
Tolbutaaide 
Ch1or,Pro,paaide 
Metahexamide 
PheD.th31b1~uanide 
Insulin (10 US.P un1 ts) 
Insulin (2 USF Wlits) 
Insulin (0.1 USF unit) 
Amt. 
wa 
10 
10 
10 
10 
S,Pec. Act. 
of sterol 
C/M/mg 
10'0 
46 
136 
139 
16 
21 
19 
NS)' 
total elM 
10,060 
9,0;0 
9,130 
9,720 
4,610 
4,920 
6,890 
8,170 
1.0 microcuriea of acetate-l-C14 was used in each incubation 
vease1. 
iii 
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cholesterol on the decreased activity of the non-saponifiable 
lipid fraction, the cbolest~rol digitonide was dissolved in two 
milliliters of acetic anhydride and an aliquot of this was 
cOUIlt •• together with the non-saponifiable lipid in a Packard 
Tri-Carb Scintillation counter. Table XI shows that after the 
subtraction of the choles~erol activity from the total non-
saponifiable lipid, the activity of the lipid fraction was still 
lower than that of controls. The hypoglycemic compounds, there-
fore, not onl~ inhibit the formation ot cholesterol but also 
the incorporation of acetate-l-C14 into the non-saponifiable 
lipid otller than cholesterol. This indicated that the inhibition 
was prior to the fo~ation of squalene. 
LOCALIZATION OF THE SITE OF ACTION 
The total non-saponifiable lipid fraction was parti-
vioned into petroleum ether from the alkaline inCUbation mixture 
after saponification with KOB. The aqeous resldue was then 
acidified to pH 1.0 with n~04. After the solution had stood at 
roo. temperature for one hour, the pH was readjusted to 10.0 
with KOH, and the ne.tral C14-1abeled substances were extracted 
with petroleum ether and the activ1t7 was determined in a 
scintillation counter. The data, shown in Table XII, indicate 
that there is a lar~e acc~ulation of the neutral petroleum ether 
I 
TABLE XI 
DISTRIBUTION O~'" RADIOACTIVITY Bb"'TltEF.lf FRAGTIO.NB 
HTpog17ceaic Agent 
None 
1'olbutam1d.e 
Ohlol.·.t?l.' o,pamide 
lIletahexaraide 
Phenetb¥lbisuanide 
Insulin 
Sterol 
C/W/mg 
1,550 
&9 
204 
208 
36 
24 
i4Si' 
C/II/mg 
ot sterol 
10,850 
5,980 
5,850 
6,075 
2,955 
3,075 
liSM' - Sterol 
9,305 
5,911 
5,&46 
5,867 
2,919 
3,051 
All hTpoglycemic compounds were used in the amount of 10 micro-
moles, with the exception ot i!.!u1in which was 10 U.S.P. units. 
0.5 microcurie. ot acetate-l-C was used in each incubation. 
"I, 
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TABLE XII 
El'FECT OF lliPOGIJYCEMIC AG~.TE OIl NW'I(kAL-C14 -COMR.>tlI~DS 
H7pogl~cemic Agent AlIt. 
WIl 
Spec. Act. 
of' sterol 
elMlms 
Neutral Cpds. 
total elM. 
0.5 m1crucuries of acetate-l-C14 was used in each incuba,ion. 
The activit3 of cholesterol was determined b, a ~as £low counter, 
whilt: that 01' the neutral COIll,t.ioWlds by a scint1llation counter. 
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soluble fraction in the inhibited mixtures. It 1s presumed, 
based on the findings of Lynen !! !!:.. (142) and Popjak (183), 
that this fraction 1s comprised of pre-squalene brunched chain 
alcohol intermooiates, 1.e., the polyprenols. The data would, 
then, sug~eat that the inhibition of cholesterol biosynthesis 
oJ the hy~oglycemlc agents takes place between lsopentenyl 
pyrophos~hate and the formation of s<lualene. Attemptss at the 
isolation and characterization of the h11:£hly active material 
obtained from neutJ.'a.l petroleum ether soluble fraction were not 
successful. 
EllfEGT Oi' HY,POGLlCEMIC AGJ.;;,NTf~ ON CO2 PRODUCTION FROM AG1!,'TATE 
Fh.n.tb¥lbi~uan1det when incubated with rat liver 
homObenates and Krebs cycle intermediates, bas been found to 
inhibit a llu.m.oer of the enzymes needed :for the decarboxylation 
of acetate (23.5). There are no reports, however, as to the effect 
of the other hypo61ycemic com.;>ounds t namely th.e 8.r'ylsulfonyl-
4reas, ou t4e CO2 production bj rat liver homo.enates. 
Tolbutamide was incubated with rat liver homoeenates 
and acetate-l-C14 and the C1402 produced waa collected and 
determined as previously described. The data, Table XIII, ahow 
that tolbl.1tamide, as did pheneth,.flbi~uanide, inhibits tLAe for-
mation 01 014°2 by rat liver homogenates. The inidbitlon 1s 
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TABLE XIII 
EltFECT Oli' TOLBUTAMIDE ON CO2 PRODUCTION OF RAT LIVEH 
HOMOGENATES 
Amount of 
tolbutamide 
in um. 
None 
4 
8 
12 
16 
20 
148 
127 
116 
84 
50 
43 
0.5 microcuries of acetate-l-C14 was used in each incubation. 
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proportional to the amount o~ tolbutamide used. A com~arison 
was made as to the extent of the inhibition of different hypo-
glycemic abents. Table XIV shows that tolbutamide, chlorpro-
pamide, aetahexamide, and inaulin inhibit the production of' 
(;14°2 from acetute to a lesser extent than vhelletb.,yl'bi..;..u~3..uide. 
That the hypoglycem1c com,pounds 1nh1b1tthe formation 
of CO2 by rat liver homogenates seems to be reasonable since 
they inhibit the f'ormation of D.P.NH and oxidize the DPNH alread1' 
present in the incubation mixture (24~). The lack of DPNH would 
result in the inhibition of the Krebs cycle and, therefore, 
would decrease the production of CO~ from acetate. 
iallenfels, CreutzfB1d and Summ (243) have found that 
tolbutamide and carbutamide in the concentrations of 10-1 and 
10-2 inhibited the reduction of DPN to DP1~1l bj' hejiatic alcohol 
and glutamic acid dehydro~enase8. The inhibition appeared to 
be compet1tive since it could be reversed by 1ncreas1~ the 
nucleotide concentration. The ox1dation or DPNll, on the other 
hand, was increased by the a..c'ylsultoIl31urea deriva'tives. It 
would seem then, that the arylsulfonylurea compounds possibly 
inhibit Cholesterol biosynthesiS by interfering with the 
formation of DPNH and oxidizing the DPNH alreadr present to DPN. 
10; 
jj;l' 1: ,t:;(';T 01' HtEOGlJi\Jl;;N1.iG \';Ulli.POui~~ 01. (;02 r'nuDu\,;i' .1.,.ii~ 01-
.ttA.'l' L.fv,U;H liO:;tUG~l'AiJ.'~ 
None 
Tolbutamide 
Ch1orj/1.'opa.m.lde 
Insulin (10 U.B.P. w:dts) 
Amt. 
wa 
10 
10 
10 
10 
Bl,)E!cii'ic Ac ti v 1 ty 
C/MI.. BaOO; 
550 
159 
;07 
251 
0.5 lnicrom .. xies 01' acetate-l-c14. was used if. eac.b. incubation. 
l04-
Since DPNH i8 needed in the formation ot 8qaalene from tarnesyl 
and nerolidyl P7rophosphatea, or more accurately in the reductio 
of dehydroaquzlene to squalene, the inhibition of cholesterol 
biosynthesis by the ar.yleulfonylureas probab17 taxes place in 
this step. 
By inhibiting the formatiou of D~~R and oxidiziDb ~ 
D.PIUi that i8 all'eadl present, the a.r;ylaultonylureas 1>revent 
the formation ot cholesterol trom its precursors. The bibh 
accuaulation of activity in the ~olrp~enols would, then, reside 
in all the intermediatea between isope.teD3l PJro~hos~ate 
and de~dros~ualene. 
Boshell, ZahDd, and Renold (37), have found that the 
administration of 3.0 grams of tolbutamide b7 mouth to fasted 
tolbutamide-responsive diabetic patients significantly decreased 
their circulating levels ot " ketone bodies". Tolbutamide in 
concentrations ot 0.2 and 1.0 asia! significantly inhibited 
ketogenesis by l1ver slices rrom fasted rata. This tolbutamide 
effect u~on hepatic ketogenesis !a vitro was also demonstrated 
ill t1.a 'pI'esenc~ .of' acetate as the substrate. .1'10 sUbgeEtion was 
made re~ardLnb tLo mochanism of the tolbutamide erfect on 
hepatic ketogenesiS in vitro. Their experiments failed to 
-
indicate where and in what form the two-carbon fragments not 
util1zed for aoetoacetute formation accumulate. Thoy have 
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sugsested that it is likelT to involve the activation of acetate 
bT •• ter linkase with CoA and tn.n condensation ot two molecules 
o! acetTl-GoA to fora acetoacetyl-eoA. The resalts obtained and 
discussed in this chapter asre. with this h¥pothesis. Since 
the formation ot alcohol P7ro~0.phates from acetate was not 
impaired '01' tolbutamid.e or azq otl;,er hypogJ..yceaic compound., 
and in fact, an accuaulation of tbe.e polyprenols results, the 
inhibition ot acetoacetate formation by tolbutamide probabl;r 
takea ,Place b3 activation ot the aceta,te to acetyl-eoA. The 
two carbon fragments not utiliaed tor acetoacetate formation 
are, therefore, probabl;r utilized for the tormation of po17-
prenola. 
Phenetqlbiguanide, when added in vi1;ro to a c.1c10-
-
phorase type enz11Jle a7at.a, AU be.n found to inhibit the Krebs 
cycl. (2,». Clo •• J.' anaqais of this ettect has silown that the 
co.~ound in concentratioDs of 10-4 ~ acta directly on the DPB 
de»endent step. of oxidation of Citrate, alpha-keto~l~tarlc aCid, 
fu.marate. oxalacetate, and p;rruvate. Tb.1a would. .ean tbat the 
reduction of DPB to DP.NH that is accollplished b7 theae reactions 
would be iapaired. Again, as in the case gf the arylsultoll¥lureaa 
the aite ot ~e inhibition is probablr in the reduction of 
dehTdrosqualene to squalene, since DPBli 18 neltd.ed. for this 
reduction. 
'I'll 
I 
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Hollunger (108) bas found that guanid1ne and 87D-thalin 
(decamet.L.eneguanid,1ne) 1:.l.t.u.bl ted the oxygen u,Ptake of m1 to-
chondria br inbibit;ing the mechani8Al that cOl.l!>lvs the oxidat1on 
at the pyridine nucleotide-cytochrome e level with phospho-
rylation. In the course of the oxidative catabolism in the 
organi .. , orthophosphate is esterifted with ADP to ATE. By this 
reaction a maJor part ot the ener~ released by the oaiaation 
i_ eonaerve4 as eheateal .aerS7 available tor e.ergr-requiring 
proce •• e. of the organ.18Dl. Guanidine a:nd srnt..b.alin, then, would 
inhibit &DT reaction that needs A2P by UDoouplina o~d&tlv. 
phosphorylation. U.oa&r, i'a;rcho;ros and Hall (2,,) have found that 
ph.elletbTlbisuanide a180 1nh1bi ta oxidat1 ve phos,Phor71ation. They I'I! 
_usseat the po8sib1lity that the prim&r.1 action of' the co.pound 
i8 on phospbor.rlation, inhibition ot oxidat1on being only 
seeoDdar7 to the 1nh1bit1on of pnosphorylation. Such a possibi-
lity ia alao su,Pported by the effect of uncoupling agents, which 
by freeing ox1dation tro. phosphorylation tend to reverse the 
effect of phenetb71biguan14e on the tricarboxylic acid c701e. 
There la, therefore, evidence to iDdicate that DPH-dopendent 
oxidative phosphorylation is the principal site of action of 
phenethylbiS1aanid.e. irOIl their results, they concluded that the 
priaarl aite of action of phenethylbl~uanide was in the electron 
transport aT&te. associated with 8uccl,nooxid.as., aore preciseJ..y 
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at a point between 8ucciniC de~drogenase and reduced cyto-
chrome c. 
InhIbition of oxidativ~ .vho:3phorylation. would resu.lt 
i.n the lack. of A"1'P for t.ll~ syntheHis of the two mevalonate 
plloB.vhates and the polyprenol P7Z'0phos¥hates. The data, however, 
ehow that these intermediate. are not inhibited by phenethyl-
bibuanide. In ract, th. formation ot ~lTprenol p¥rophos~ates 
is potentiated boY .phenetL.ylbi~uanide. The ~;e8u.lts, there;fore, 
do not sup~ort the bypathesis that th, site of action of phen-
eth¥lbi~uan1de 1s the inh1bl~lon of oxidative ~nos¥hurylation. 
'fhis 1s true, at least, ill the 578tea that was used for the 
experiment8. It is true that Ungar 11 ~ (235) used a mito-
chondrial sTot •• for their experiments, while the author used 
a combination of soluble, microsomal, and mitochondrial 
preparation for his studies. RecentlJr We1nbach (247) has found 
that when cytoplasmic preparations .ere used another mechanism 
could phosphorylate ADP whell the oxidative ,Phos,P!lo.t'j'lation was 
uncouj>led. He found that al'thoUfSh the oxidative phos,phor,ylation 
W.J.S uncou.pled, there was an increase in phosphoenolii;iruvate. 
B7 tt .. e action ot a kinase, pho&,Phoenol'pyruvate can 'phos~b.or'ylat. 
ADI' to A!fP. The phospho1"l'lation of Al'F br oxidative yhoSklhory-
lation, therefore, car, be bY'passed in non-mitochondrial ~re~a­
rations. The results,then, do not contradict Ungar's bJpothesi8 
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that pheneth¥lbi~uan1de inhibits oxidative phosphorylation. 
l'rocaine has been shown to deerease atherosclerotic 
lesions (10), the Cholesterol level of the blood (218), and the 
blood pressure ot hypertensive patients (45). Although procaine 
is not a b¥poglycemlc compound .. it does, however, red.u.ce th4it 
Cholesterol level of the blood. Procaine, therefore, was inclu-
ded in the studies of the e1'1'fotcts of certain compounds on 
cholesterol biosynthe51s. Incubations were made with procaine 
in the same way as was done with the h.;r].loglyceBdc COD1,poWlds. 
The results that were obta1ned, shown in Table XV, indicate 
that procaine does inhibit the biosynthesis of Cholesterol. 
The inhibition is proportional to the amou.ut of procaine bJ"aro-
chloride used. 11.be effect was not due to .pH ehanses due to the 
different amounts of procnine hydrochloride as snown by 
Table VIII. The effect of procaine hydrochloride on the incor-
poration of acetate-l-C14 into cholesterol is not as great as 
t.b.at of' the hypogl.rc(~m1c compounds. A com.parison of the effects 
of all compounds used in the investigation on cholesterol bio-
synthesis is shown in Jigure VII. ~herea8 the inhibition of 
cholesterol bios3nthesi& was almost oomplete with 10 micromoles 
ot the hy~oglyc~mie compounds, 10 .le~omole8 of procaIne 
jl 
I 
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TA.BLE XV 
Dli'ECT OF mOCAIli.&; Oli 'lIfE Blu!3X'Nl'HEBIS OF CBOLESTJS.ROL 
iulount of 
procaine 
i.u WI. 
Jone 
10 
20 
50 
40 
opeo. Act. 
oi' sterol 
elM/JAg 
1664 
552 
~02 
207 
1:"7 
" Inhibition 
~.8 
81.8 
0.5 :mierocuries of aeetate-l-c14 waR llsed 1n each 1ncubtttlon. 
z 
o 
I-
CD 
-J: 
z 
I-
Z 
LLJ 
u 
a::: 
LLJ 
a.. 
100 
80 
60 
40 
20 
110 
-~-----------
e-
/' 
e~ 
e 
/ 
e 
10 20 
INHIBITOR 
FIGURE VII 
30 40 
(fLM) 
-e-
50 
IlII{)GLYC~MIC COW?OC.NOO Al~D P11.0CAI.m~ 
Open c1rcles- hypoglycemic compounds. Closed circles - procaine. 
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inhibited the cholesterol biosynthesis b,y only 43 per cent. 
BYen at high concentrations (50 .ioro.olea), procaine did not 
oo.~letely halt the incor»oration of ~cetate-l-c14 into chole-
sterol b¥ ~~t liver no~o6~nates. 
'fhe <fbserved decrease in blood. cholesterol ai'ter 
tu~ adm~stration of grocaiue 41d~ochlor1a. is, thereto~., 
JrIl."obablj d.uo to t:o.e :in.tU.b1 tion 01' cholesterolbiosYI.!tlieais. 
The action of procaine and the ~vo~lycemic compounds, 
tolbutamide, chlorpropamide, metahexamide, and phenethylb1gunide, 
on the biosynthesis of cholesterol have been investigated b,y 
the use of rat liver homogenates, the necessary cofactors, 
and acetate-l-Cl4• The results show that the incorporation of 
acetate-l-C14 into cholesterol is inhibited by all by~o~lycemic 
compounds to ap~roximatel3 the same extent. The inhibition of 
cholesterol bios~~thealR b~ procaine h¥droehloride, although 
very significant, is mucn lower than that of the b.Y~ogl'ycem1c 
compounds. 
The data also sbow that the inhibItion ot cholesterol 
biosynthcsi!'S by the hypof>lyceL"lie eoopoul:l.ds tukes place between 
the 18o'p~nt.ll31 pyrophosphate and the formatioD. of sq,utllene, 
.\fos;;i tly at the red:llcti.Ort ntc,P 01: dehyd.1:'o5q,ua1ene. It 1 f' 
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~robab1y due to the inhibition ot DP.NH formation fro~ DPfi and 
the oxidation of Dl~H to DPN by the hypoglycemic compounds. 
The inhibition of the Krebs cycle, as .aasured by C1402 
production, by phenethylbi~uan1de was confirmed. The data also 
show that the other h3poglycemic com~und8 also inhibit the 
production of CO2 b3 the rat liver homoganates, altho~l to a 
lesser 81tent than ~henethylbl~uanlde. 
Tho data supports the theory of Boshell at ale (37) 
--
that the two-carbon fra&ments not uti~lzed tor acetoacetate 
toraatitJIl atter incubation with tolbutamide arc activated to 
acetyl-Co.A. The inhibition of oxidative phosJ,J.b.or.rlatlon by 
'phenet.iqlb1gua.n14e, as re,POrted b7 UD6Ar !!. !.!!.. (235), was not 
obtaine4 in the s¥stea studied. 07to~laamie ~hospUorrlation ot 
A'lI,P is probably responsiblo for the d1fferene!;: in results. 
Procaine hydrochloride, which reduce. cholesterol !a 
!'!!.2, has been tound. to inhlbi t cholesterol blo81ntl .. esis !!! 
vitro. The data, partial17, explains the lowering ot blood chole 
eterol reported bj" other 1nvestigators. 
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PAB!' I 
IUTBRIAh.'> .AND Ml':THODB 
lreR!Fatlon of the St!94'£4 Buffer solutlon: 
140 
The standard bu1':fer solutlon used in all incubatlona 
-.. ,prepared LCJ follows: 11.514 g. of K~P04 (\8. Mallinckrocl t 
Cheaical Co.), 1.815 g. of i.H2P04 (AR, Baker and AdaJlaon Che-
meal Co.), 0.978 I. of M6Cl2 .6H20 (AR, Ilallinor04t Chemical Co. 
aDd '.664 5. of niootlnamide (lot # 3351, Nutritional Bloohemi-
cals), was made up to one liter with doub~ • glass dlstllled 
water. ~he tinal aolarit7 ot the solutlon was 0.08 K wlth 
re.peot to phosphate, 0.0' ~ with respect to nicotlnaaide, 
and 0.0048 K with rQ~peot to MgCl2. ~he pH, as measured by a 
Beckman pH meter, was tl.4. 
~eaarat!on of aelf-absorption curve tor cholesterol digitonide: 
li'roll eata in ~aul. IV t l>fl.6e 75 t tl.t~ a,Pparent specifio 
aetlvlt7 (e/m/as) was plotted against sample welbht per unit 
are. (.Ilt./cm2){~'1&\U'. VIII). The curve waa extra»olated to zero 
thickneas and the "aaximum &vparent a!)eol!lc activity" was 
obtained. Usi.r:.Lg this value t the 1'ractlon of' the "alUdmWil speci-
f1c actlvity" was calculated by dividing the speelrlc actlv1tr 
ln ~able IV b7 the "maxi&um &vvaL'ent s»eelflc act1v1ty (Table 
XVI). The tract10n wau then ~lotted against tbe weight per unit 
141 
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TABJ.Jl: XVI 
~B~ FRACTIO~ Oi TH]; SPECIFIC ACTIVITY 
--
1050 o.~ 
705 0.43 
11.8 0.2'1 
390 0.24 
16.8 351 0.20 
14, 
area (ag/CIIl2) and 'the .elf-absorption curve tor cholesterol 
dis1ton1de that appears 1n l1gure III • .pase 76. was constructe4. 
1.11'1' II
II 
. 
TABU nIl 
(Figure I~ Pa6- 61) 
STANDARD CHOLESTEROL CUaVB 
• 
Cholesterol net tReading 
--" 
..........-.---. p 
2.0 12 
13 
4.0 27 
29 
6.0 49 
50 
8.0 68 
64 
10.0 93 
83 
12.0 11~ 
108 
14.0 1~ 
138 
10.0 156 
152 
18.0 173 
11, 
20.0 191 
19, 
Avera&o 
12.5 
28.0 
49.5 
&6.(; 
91.0 
il 
Ii 
110.5 I I 
II 
1,,4.0 
iii 154.0 
I 
17;>.0 
Ii 192.0 
1\ 
,1,,1 
1
11
'1' 'i 
~ I 
\1 
illl 
"1111 
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.PART II 
.u~ ECT OF HI.POG.i.lICEdIC AGENTS AND .PROCAINb ON 
CHOLESTEROL BrOSI~THESIS 
TABLE XVIII 
Amount of' Specific Act1v1ty Average 
tolbutam.id.e of' cholesterol 
1n WI. Cl1A1Jaf5 
None 1118 
12}2 1220 1270 
1110 
4 510 
486 504 498 
522 
8 163 
161 151 141 
139 
12 7~ 
80 71 62 
67 
16 44-
42 46 4-8 
50 
20 47 
48 45 42 
43 
:i)1 
I11I 
IIII 
1,1, 
I ~, I 
::iIi, 
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fABl& XIX 
U~.ECT OF .PHENETHYLBIGUANIDE ON CHOLE.<;TLtiOL BIOS!.NTHESIS 
Aliount of SpecIfIc Actlvitr Average 
PUG (ua) of cholesterol 
C/¥/y 
• 
None 1496 
1545 1610 1722 
1675 
2 1345 
1271 1340 1285 
1418 
4 869 
,ii 708 788 768 II,) 
726 
4!;>5 
455 455 402 
448 
8 330 
349 342 35, 
335 
10 25 
41 33 27 
39 
ill 
I 
IIII 
1''I1 ill,II, 
14? 
TABL..:.: 1...X 
E.F.'fl1NT OF arroGI,YCEMIC AGEffTS ON NOl~-8APONIJ1I.tlBM LIllID 
AliD CHOLEST1'f:ftOL BIOBn"iTHESIB 
Hypoglycemic Agent 
Bone 
Tolbutamide 
Ch1or,propamide 
Metahexamlde 
P.benetbTlbiguanide 
Insulin (10 units) 
Insulill (2 un1 ts ) 
NSL 
0.1 a11q. 
cpa 
1804 
1588 
1620 
1411 
934-
8?? 
85; 
949 
1081 
1025 
774-
781 
948 
98& 
eno 
984 
382 
569 
535 
3lj7 
532 
461 
5>8 
41? 
622 
709 
669 
756 
Average HSL 
Total cpa (aliq. 
x 10-1 
1600 16,060 
915 
972 9.720 
4-61 4.610 
4.920 
689 6,890 
Hrpoglyceaic Agent 
Insulin (0.1 units) 
TABLE XX 
(CONTINUED) 
.NSL 
0.1 allq. 
cpDl 
802 
820 
814 
832 
Averaese 
817 
148 
SSL 
Total cpa {aliq. 
x 10-1 
8,170 
14 . 1.0 micro.oles of acetate-l-C was' used in each incubation. 
The amount of inhib1tors was 10 aicromoles exc.~t where 
spec1f1ed otherwise. 
Bone 
folbutamide 
ChloJlpropa.ra1de 
Met abexa.aid e 
Pbenetbylb1guanide 
Insulin (10 un1ts) 
Spec. Act. 
of sterol 
C/M/ag 
10;; 
1027 
50 
41 
10} 
169 
14" 
1;5 
26 
21 
12 
20 
Average 
1030 
46 
136 
139 
2lt 
16 
149 
B3,Pog13cemic Agent .t-fbL Averat{;e liS.u 
0.2 aliq. Total cJ:& (ali",. 
cgm x 1/5 
None 128; 
1256 1;01 u,505 13.29 
1346 
Tolbutamide 54? 
459 4'18 2,';90 444-
45? 
Ch1orpropaatde 474 
535 525 2 t C>25 512 
56? 
ACetahexamide 577 
527 547 2.7'5 51? 
526 
Insulin (10 units) 51? 525 2,625 53; 
Insulin (2 units) 559 509 2.84-5 578 
0.5 micro.oles of acetate-1-C14 was used in each incubation. 
Unless specified, the amount of the inhibitors used was 
10 microJlol.a. 
I 
':1 
I 
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T.ABLI XXII 
])I~~TRIBUTIO)f OF RADIOACTIVITI B'i'WJ&a fHE i'RACfIOllS 
B7pos1¥cwmic Agent Sterol Ave. l{bL Ay •• 
cpa/ .. cpm/as 
of aterol 
" 
None 1517 10,14' 
1;2' 1;50 10,957 10.850 
Tolbutamide 75 5.%3 
63 69 5,997 5,980 
Chlor'pzoo,paa14e 215 5,1';1 
193 204 5,9't!> 5.850 
.... tah.x .. 14. 176 6,214 
241 208 ;,936 6.075 
PhenetbTlb1guan1de 41 2,992 
32 36 2,918 2,955 
In8ulin (10 units) 24 2,974-
25 24 },l?i ',015 
0.5 microcurie. of acet •• -1-C14 was used in each incubatioa. 
Unl ••• s,peolt1ed, all .b1poglrcemic compounds •• .to \laod in 
the aaount of 10 micro.olea. 
• 
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'fABLE XXIII 
lU'i.iCT OF HlroGLYCRIC AGE.NTE 0.1 BEUTRA.li-C14 -OOMFOU.MJS 
B;ypogqcell1o Asent Beutral O,pc:1s. Ave. .Neutral 0148. 
0.1 a~1quot total epa 
cpa (a11q. x 10-1 ) 
None 65 
71 61.8 678 b8 
07 
Ohlorpropaa1de 893 
922 910 9,100 927 
898 
Insulin (10 units) 915 
9'78 990 9,900 1065 
1002 
Pheneth¥lbiguani4e 1061 
988 1029 10.2'10 1070 
991 
i&etahexamide 1104 
1213 116't 11,EiA-O 1224 
lOlb 
l'olbutaaide 1189 
11'9 1211 12,110 1283 
12" 
Unle.s specified, tbe aaount ot b;1.P06Qo81l1e coapoUD4s was 
10 micro.ol ••• 
0.5 microcuri •• o~ acetate-l-c14 was used 1D each iacubatAon. 
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TABLE XXIV 
DFECT OF TOlABUTAMIl)E Oll 002 .PRODUOTIOB 01 RAT LrVltR 
HO?'~GrJ!iNA'r~ 
MOunt of 
tolbutamide 
in um 
hone 
8 
12 
16 
20 
156 
140 
1?8 
ll7 
10& 
126 
85 
84 
59 
41 
Average 
148 
127 
116 
0.5 microcurie. of acetate-l-c14 was used in each incubation. 
I 
II 
I 
,I 
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TABLE: XXV 
lfiIl/}I.O'l OJ'' aIJ?OO.Llv~;'IC COMPOliNDS 011 002 PRODUCT 10M 01 iUt 
!trv llJi liJaQG.i!ll:iA1:ES 
• . •• b 
Hyj:los17aea1e Agent :aaC140 
C/il/ag' 
Average 
n _ R 
-
... 
.Ioae 561 
5}3 550 
Fhen.thylb16~nlde 166 
152 15'3 
-rol bu. t amide '71 
264 '07 
Clllorpropaaide 29; 214-255 
Metahexam1<le 207 
20; 2;~ 
Insulin (IO units) 293 
207 251 
Unless speoified, tne amoWlt of hypoglycemic COlil,POWlds that 
was used 1n each incubation was 10 aicroaol ••• 
-
0.5 microourie. of ac8t&t8-1-o14 was us$d in each incubation. 
-.,1 
TABLE ~lVI 
... .., I' 
" r • • I .... ~ .. 
, .... ... .. • r 
DOunt of Spec. Act. Avorage 
prooa1Ae of sterol 
in ua C/'ttI./q 
• F . . . . .. . • . . . • • 
Bone 16}9 1664 
1S89 
10 979 94' 908 
20 ,20 ;,2 
58!) 
}O }O5 302 }OO 
40 159 
255 201 
50 166 157 
14? 
0.5 Mierocur1es of acetate-l-c14 wes used in each inoubation. 
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The thesis submitted by John ]ti. Da11dowicz has been 
read and. alJPl"oved D1' three m.embers of the facu.lty ot Lorola 
Uni vera1tT. 
~he final CO~i.8 have been eJU:Unined 'boY tn.e dirttctor 
ot the tActS!S and the sibnat~e which a¥~ear8 below verities 
the fact that necessary cDaDties have; Dven 1ncor.vorated, and 
that the thesis is now given 1'iual &.v.vroval with reterenee 
to COllt~Jlt, :fora, and mechauical accuracl'. 
The thesis is there~ore acce~ted in partial 
fulfillment of the require.ents for the Degree of Master of 
Science. 
